

JUST ANNOUNCED

ALEXANDRIA EXECUTES LARGEST LIFE SCIENCE LEASE IN COMPANY HISTORY WITH A LONG-STANDING MULTINATIONAL PHARMACEUTICAL TENANT IN JULY FOR A 466,598 RSF BUILD-TO-SUIT RESEARCH HUB AT OUR CAMPUS POINT BY ALEXANDRIA MEGACAMPUS™ IN SAN DIEGO



HIGHLIGHTS

- 16-year lease term with a credit tenant
- Underscores uniquely targeted demand for our leading life science destination in San Diego
- R&D hub embedded in an amenity-rich Megacampus ecosystem that enables tenants to recruit and retain top talent

Table of Contents

June 30, 2025



COMPANY HIGHLIGHTS	Page		
Mission and Cluster Model	iii		
EARNINGS PRESS RELEASE	Page		Page
Second Quarter Ended June 30, 2025 Financial and Operating Results	1	Consolidated Statements of Operations	8
Guidance	5	Consolidated Balance Sheets	9
Dispositions and Sales of Partial Interests	6	Funds From Operations and Funds From Operations per Share	10
Earnings Call Information and About the Company	7		
SUPPLEMENTAL INFORMATION	Page		Page
Company Profile	13	External Growth / Investments in Real Estate	
Investor Information	14	Investments in Real Estate	32
Financial and Asset Base Highlights	15	New Class A/A+ Development and Redevelopment Properties:	
High-Quality and Diverse Client Base	17	Recent Deliveries	34
Internal Growth		Current Projects	35
Key Operating Metrics	20	Summary of Pipeline	39
Same Property Performance	21	Construction Spending	44
Leasing Activity	22	Capitalization of Interest	45
Contractual Lease Expirations	23	Joint Venture Financial Information	50
Top 20 Tenants	. 24	Balance Sheet Management	
Summary of Properties and Occupancy	. 25	Investments	52
Property Listing	26	Balance Sheet	53
		Key Credit Metrics	54
		Summary of Debt	55
		Definitions and Reconciliations	
		Definitions and Reconciliations	60

CONFERENCE CALL INFORMATION:

Tuesday, July 22, 2025

2:00 p.m. Eastern Time 11:00 a.m. Pacific Time

(833) 366-1125 or (412) 902-6738

Ask to join the conference call for Alexandria Real Estate Equities, Inc.

CONTACT INFORMATION:

Alexandria Real Estate Equities, Inc. corporateinformation@are.com

JOEL S. MARCUS

Executive Chairman & Founder

PETER M. MOGLIA Chief Executive Officer & Chief Investment Officer

MARC E. BINDA Chief Financial Officer & Treasurer

Managing Director, Rx Communications Group (917) 633-7790

OUR MISSION

To create and grow life science ecosystems and clusters that ignite and accelerate the world's leading innovators in their noble pursuit to advance human health by curing disease and improving nutrition

OUR CLUSTER MODEL

Alexandria has identified four critical components for life science companies to thrive: *location*, *innovation*, *talent*, and *capital*.

Our proven cluster model unites cutting-edge innovation with leading scientific and managerial talent and strategic investment capital in best-in-class locations immediately adjacent to some of the world's top academic institutions.



THAT'S WHAT'S IN

WE INVENTED IT.

WE DOMINATE IT.

THE MOST TRUSTED BRAND IN LIFE SCIENCE REAL ESTATE

LARGEST, HIGHEST-QUALITY ASSET BASE CLUSTERED IN THE BEST LOCATIONS


SECTOR-LEADING CLIENT BASE OF ~750 TENANTS

HIGH-QUALITY CASH FLOWS

PROVEN UNDERWRITING

FORTRESS BALANCE SHEET

LONG-TENURED, HIGHLY EXPERIENCED MANAGEMENT TEAM



ALEXANDRIA'S MEGACAMPUS[™] PLATFORM DRIVES SUPERIOR OPERATING RESULTS



ALEXANDRIA'S MEGACAMPUS PLATFORM

ALEXANDRIA'S MEGACAMPUS OCCUPANCY OUTPERFORMS THE MARKET⁽¹⁾

75%

of Annual Rental Revenue

91%

Megacampus

74%

Market

17%

Occupancy Outperformance

As of June 30, 2025. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) Represents the occupancy at Alexandria's Megacampus ecosystems within the Greater Boston, San Francisco Bay Area, and San Diego markets as of June 30, 2025, compared to the average market occupancy for these markets per the Q1 2025 U.S. Life Sciences Report published by CBRE Research.

INNOVATION IS THE DRIVING FORCE BEHIND THE LIFE SCIENCE INDUSTRY'S GROWTH AND REPRESENTS AN IMMENSE OPPORTUNITY FOR THE FUTURE







CRITICAL FOR NATIONAL HEALTH AND SECURITY

Innovation in life science is critical for maintaining a stronger, safer, and healthier country, as well as for America's global life science leadership and future economic growth.


ADDRESSES MASSIVE UNMET MEDICAL NEED

With more than 10,000 diseases, over 90% of which still have NO approved treatments,⁽¹⁾ significant innovation in life science will remain imperative.

DELIVERS RELENTLESS INNOVATION

The life science industry is fueled by new discoveries coming out of academia, biotech, and pharma. The U.S. has the best substrate in the world to continue to drive the research, development, and commercialization of new medicines well into the future.

⁽¹⁾ Source: U.S. House Committee on Energy and Commerce, "The 21st Century Cures Discussion Document White Paper," January 27, 2015.



⁽¹⁾ Source: U.S. House Committee on Energy and Commerce, "The 21st Century Cures Discussion Document White Paper," January 27, 2015

⁽²⁾ Source: PhRMA, "Medicines in Development for Chronic Diseases: 2024 Report."

⁽³⁾ Source: Centers for Disease Control and Prevention, "Heart Disease Facts," October 24, 2024. Represents the latest published data, which reflects U.S. estimate for 2022.

⁽⁴⁾ Source: National Cancer Institute, "Cancer Statistics," updated May 7, 2025. Represents the latest published data, which reflects 2018–2021 data, not including 2020 due to COVID.

⁽⁵⁾ Source: Alzheimer's Association, "2025 Alzheimer's Disease Facts and Figures." Represents the latest published data, which reflects the U.S. estimate for 2025.

BIOTECH INNOVATION IS DIRECTLY RESPONSIBLE FOR OVER **60% OF TOP 20 PHARMA REVENUE**



NOTABLE APPROVALS BY ALEXANDRIA TENANTS





Johnson&Johnson

First-in-class medicine used to treat schizophrenia and bipolar depression







First approved therapy for patients with cystic fibrosis








Transformative cell therapy for multiple forms of B-cell lymphomas

With Biotech⁽¹⁾

⁽¹⁾ Source: Evaluate Pharma, May 27, 2025. Represents percentage of top 20 biopharma product sales generated from M&A and partnerships in 2024. M&A includes company and product acquisitions. Partnerships include products sourced by a company through in-licensing deals.

ALEXANDRIA'S HISTORICALLY CONSISTENT AND SOLID DIVIDENDS



⁽¹⁾ Dividend yield is calculated as the dividend declared for the three months ended June 30, 2025 of \$1.32 per common share annualized divided by the closing price of our common stock on June 30, 2025 of \$72.63.

⁽²⁾ Represents the aggregate sum for the years ended December 31, 2021 through 2024 and the midpoint of our 2025 guidance range. Refer to "Guidance" in the Earnings Press Release for additional details.

⁽³⁾ Represents the common stock dividend declared of \$1.32 per share for the three months ended June 30, 2025 annualized.



ALEXANDRIA.

AT THE VANGUARD AND HEART OF THE LIFE SCIENCE ECOSYSTEM™

Alexandria Real Estate Equities, Inc. Reports:

2Q25 and 1H25 Net Loss per Share – Diluted of \$(0.64) and \$(0.71), respectively; and 2Q25 and 1H25 FFO per Share – Diluted, as Adjusted, of \$2.33 and \$4.63, respectively

PASADENA, Calif. – July 21, 2025 – Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced financial and operating results for the second quarter ended June 30, 2025.

Key highlights

Operating results		2Q25		2Q24		1H25		1H24
Total revenues:								
In millions	\$	762.0	\$	766.7	\$	1,520.2	\$	1,535.8
Net (loss) income attributable to Alexandria's common stockholders – diluted:								
In millions	\$	(109.6)	\$	42.9	\$	(121.2)	\$	209.8
Per share	\$	(0.64)	\$	0.25	\$	(0.71)	\$	1.22
Funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted:								
In millions	\$	396.4	\$	405.5	\$	788.4	\$	809.4
Per share	\$	2.33	\$	2.36	\$	4.63	\$	4.71

A sector-leading REIT with a high-quality, diverse tenant base and strong margins

(As of June 30, 2025, unless stated otherwise)		
Occupancy of operating properties in North America	90.8%	(1)
Percentage of annual rental revenue in effect from Megacampus™ platform	75%	
Percentage of annual rental revenue in effect from investment-grade or publicly traded large cap tenants	53%	
Operating margin	71%	
Adjusted EBITDA margin	71%	
Percentage of leases containing annual rent escalations	97%	
Weighted-average remaining lease term:		
Top 20 tenants	9.4	years
All tenants	7.4	years
Sustained strength in tenant collections:		
July 2025 tenant rents and receivables collected as of July 21, 2025	99.4%	
2Q25 tenant rents and receivables collected as of July 21, 2025	99.9%	

(1) Reflects temporary vacancies aggregating 668,795 RSF, or 1.7%, which are now leased and expected to be occupied upon completion of building and/or tenant improvements. The weighted-average expected delivery date is January 2, 2026.

Strong and flexible balance sheet with significant liquidity; top 10% credit rating ranking among all publicly traded U.S. REITs

- Net debt and preferred stock to Adjusted EBITDA of 5.9x and fixed-charge coverage ratio of 4.1x for 2Q25 annualized, with 4Q25 annualized targets of ≤5.2x and 4.0x to 4.5x, respectively.
- · Significant liquidity of \$4.6 billion.
- Only 9% of our total debt matures through 2027.
- 12.0 years weighted-average remaining term of debt, longest among S&P 500 REITs.
- Since 2021, our guarter-end fixed-rate debt averaged 97.2%.
- Total debt and preferred stock to gross assets of 30%.
- \$297.3 million of capital contribution commitments from existing real estate joint venture partners to fund construction from 3Q25 through 2027 and beyond, including \$116.7 million from 3Q25 to 4Q25.

Leasing volume and rental rate increases

- Leasing volume of 769,815 RSF during 2Q25.
- In July 2025, we executed the largest life science lease in company history with a long-standing multinational pharmaceutical tenant for a 16-year expansion build-to-suit lease, aggregating 466,598 RSF, located on the Campus Point by Alexandria Megacampus in our University Town Center submarket. If this were included in the leasing volume for 2Q25, the total leased RSF would have increased to 1.2 million RSF for 2Q25 from 769,815 RSF. Refer to "Subsequent events" in the Earnings Press Release for additional details.
- Rental rate increases on lease renewals and re-leasing of space of 5.5% and 6.1% (cash basis) for 2Q25 and 13.2% and 6.9% (cash basis) for 1H25.
- 84% of our leasing activity during the last twelve months was generated from our existing tenant base.

	2Q25	1H25
Total leasing activity – RSF	769,815	1,800,368
Lease renewals and re-leasing of space:		
RSF (included in total leasing activity above)	483,409	1,367,817
Rental rate increase	5.5%	13.2%
Rental rate increase (cash basis)	6.1%	6.9%
Leasing of development and redevelopment space – RSF	131,768	138,198

<u>Dividend strategy to share net cash flows from operating activities with stockholders while</u> retaining a significant portion for reinvestment

- Common stock dividend declared for 2Q25 of \$1.32 per share aggregating \$5.26 per common share for the twelve months ended June 30, 2025, up 18 cents, or 3.5%, over the twelve months ended June 30, 2024.
- By maintaining our recent dividend at \$1.32 per share, over \$40 million of additional liquidity and equity capital can be reinvested annually.
- Dividend yield of 7.3% as of June 30, 2025.
- Dividend payout ratio of 57% for the three months ended June 30, 2025.
- Significant net cash flows provided by operating activities after dividends retained for reinvestment aggregating \$2.3 billion for the years ended December 31, 2021 through 2024 and the midpoint of our 2025 guidance range.

Ongoing execution of Alexandria's 2025 capital recycling strategy

We expect to fund a significant portion of our capital requirements for the year ending December 31, 2025 through dispositions of non-core assets, land, partial interest sales, and sales to owner/users. We expect dispositions of land to represent 20%–30% of our total dispositions and sales of partial interests for 2025.

(in millions)		
Completed dispositions	\$ 261	
Our share of pending transactions subject to non-refundable deposits, signed letters of intent, and/or purchase and sale agreement	505	
negotiations	 525	
Our share of completed and pending 2025 dispositions	786	40%
Additional targeted dispositions	1,164	60
2025 guidance midpoint for dispositions and sales of partial interests	\$ 1,950_	100%

Second Quarter Ended June 30, 2025 Financial and Operating Results (continued)

June 30, 2025



Alexandria's development and redevelopment pipeline delivered incremental annual net operating income of \$15 million commencing during 2Q25, with an additional \$139 million of incremental annual net operating income anticipated to deliver by 4Q26 primarily from projects 84% leased/negotiating

- During 2Q25, we placed into service development and redevelopment projects aggregating 217,774 RSF that are 90% occupied across three submarkets and delivered incremental annual net operating income of \$15 million.
 - A significant 2Q25 delivery was 119,202 RSF at 10935, 10945, and 10955 Alexandria Way located in this asset at the One Alexandria Square Megacampus in our Torrey Pines submarket.
 - Improvements of 100 bps and 110 bps in initial stabilized yield and initial stabilized yield (cash basis), respectively, were primarily driven by leasing space at higher rental rates than previously underwritten and a \$23 million reduction in total investment due to construction cost savings from overall project efficiencies.
- Annual net operating income (cash basis) from recently delivered projects is expected to increase by \$57 million upon the burn-off of initial free rent, which has a weighted-average burn-off period of approximately three months.
- During 1Q25-4Q26, we expect to deliver annual net operating income representing nearly 9% of the total net operating income for 2024.
- 74% of the RSF in our total development and redevelopment pipeline is within our Megacampus ecosystems.

Development and Redevelopment Projects	Anni	emental ual Net ng Income	_	RSF		Leased/ Negotiating Percentage
(dollars in millions)						
Placed into service:						
1Q25	\$	37		309,494		100%
2Q25		15	(1)	217,774		90
Placed into service in 1H25	\$	52	(1) =	527,268		96%
Expected to be placed into service:						
3Q25 through 4Q26	\$	139	(2)	1,155,041	(3)	84% (4)
2027 through 2028 ⁽⁵⁾		261		3,270,238		28%
	\$	400				

- Excludes incremental annual net operating income from recently delivered spaces aggregating 22,005 RSF that are vacant and/or unleased as of June 30, 2025.
- (2) Includes expected partial deliveries through 4Q26 from projects expected to stabilize in 2027 and beyond, including speculative future leasing that is not yet fully committed. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for additional details.
- (3) Represents the RSF related to projects expected to stabilize by 4Q26. Does not include RSF for partial deliveries through 4Q26 from projects expected to stabilize in 2027 and beyond.
- (4) Represents the leased/negotiating percentage of development and redevelopment projects that are expected to stabilize during 2H25 and 2026.
- (5) Includes one 100% pre-leased committed near-term project expected to commence construction in the next year.

Significant leasing progress on temporary vacancy

Occupancy as of June 30, 2025	90.8%	(1)
Temporary vacancies now leased with future delivery	1.7	(2)
Occupancy as of June 30, 2025, including leased, but not yet delivered space	92.5%	

- 1) Refer to "Summary of properties and occupancy" in the Supplemental Information for additional details.
- (2) Represents temporary vacancy as of June 30, 2025 aggregating 668,795 RSF, primarily in the Greater Boston, San Francisco Bay Area, and San Diego markets, which is leased and expected to be occupied upon completion of building and/or tenant improvements. The weighted-average expected delivery date is January 2, 2026.

Key operating metrics

- Net operating income (cash basis) of \$2.0 billion for 2Q25 annualized, up \$111.4 million, or 5.8%, compared to 2Q24 annualized.
- Same property net operating income changes of (5.4)% and 2.0% (cash basis) for 2Q25 over 2Q24 and (4.3)% and 3.4% (cash basis) for 1H25 over 1H24, which include lease expirations that became vacant during 1Q25 aggregating 768,080 RSF across six properties and four submarkets with a weighted-average lease expiration date of January 21, 2025. Excluding the impact of these lease expirations, same property net operating income changes for 2Q25 would have been (2.1)% and 6.5% (cash basis). As of June 30, 2025, 153,658 RSF was leased with a weighted-average lease commencement date of April 30, 2026, and we expect to favorably resolve the remaining 614,422 RSF over the next several quarters.
- General and administrative expenses of \$59.8 million for 1H25, representing cost savings of \$31.9 million or 35%, compared to 1H24, primarily the result of cost-control and efficiency initiatives on reducing personnel-related costs and streamlining business processes.
 - As a percentage of net operating income, our general and administrative expenses for the trailing twelve months ended June 30, 2025 were 6.3%, representing the lowest level in the past ten years, compared to 9.2% for the trailing twelve months ended June 30, 2024.

Strong and flexible balance sheet

Key metrics as of or for the three months ended June 30, 2025

- \$25.7 billion in total market capitalization.
- \$12.4 billion in total equity capitalization.

	2Q	25	Target
	Quarter Trailing Annualized 12 Months		4Q25
			Annualized
Net debt and preferred stock to Adjusted EBITDA	5.9x	5.8x	Less than or equal to 5.2x
Fixed-charge coverage ratio	4.1x	4.3x	4.0x to 4.5x

Second Quarter Ended June 30, 2025 Financial and Operating Results (continued)

June 30, 2025



Strong and flexible balance sheet (continued)

Key capital events

- Upon maturity on April 30, 2025, we repaid \$600.0 million of our 3.45% unsecured senior notes payable with proceeds from our February 2025 unsecured senior notes payable offering.
- Under our common stock repurchase program authorized in December 2024, we may repurchase up to \$500.0 million of our common stock through December 31, 2025. During 2Q25, we did not repurchase any shares. As of July 21, 2025, the approximate value of shares authorized and remaining under this program was \$241.8 million.
- In August 2025, we expect to repay a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, a development project where we have a 76.9% interest. The project is currently 76% leased/negotiating and is expected to deliver in 2026. We expect to repay the loan aggregating \$153.5 million which matures in 2026 and bears an interest rate of 7.16% as of June 30, 2025. As a result, we expect to recognize a loss on early extinguishment of debt of \$99 thousand for the write-off of unamortized deferred financing costs in 3Q25.

Investments

- As of June 30, 2025:
 - · Our non-real estate investments aggregated \$1.5 billion.
- Unrealized gains presented in our consolidated balance sheet were \$7.7 million, comprising gross unrealized gains and losses aggregating \$180.2 million and \$172.5 million, respectively.
- Investment loss of \$30.6 million for 2Q25 presented in our consolidated statement of operations consisted of \$30.5 million of realized gains, \$21.9 million of unrealized losses, and \$39.2 million of impairment charges.

Other key highlights

Key items included in net income attributable to Alexandria's common stockholders:

	2Q25	2Q24	2Q25	2Q24	1H25	1H24	1H25	1H24	
(in millions, except per share amounts)	Amo	Amount		Per Share – Diluted		Amount		Per Share – Diluted	
Unrealized losses on non- real estate investments	\$ (21.9)	\$ (64.2)	\$ (0.13)	\$ (0.37)	\$ (90.1)	\$ (35.1)	\$ (0.53)	\$ (0.20)	
Gain on sales of real estate	_	_	_	_	13.2	0.4	0.08	_	
Impairment of non-real estate investments	(39.2)	(12.8)	(0.23)	(80.0)	(50.4)	(27.5)	(0.30)	(0.16)	
Impairment of real estate ⁽¹⁾	(129.6)	(30.8)	(0.76)	(0.18)	(161.8)	(30.8)	(0.95)	(0.18)	
Increase in provision for expected credit losses on financial instruments					(0.3)				
Total	\$(190.7)	\$(107.8)	\$ (1.12)	\$ (0.63)	\$(289.4)	\$ (93.0)	\$ (1.70)	\$ (0.54)	

 Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release for additional details.

Subsequent event

- In July 2025, we executed the largest life science lease in company history with a longstanding multinational pharmaceutical tenant for a 16-year expansion build-to-suit lease, aggregating 466,598 RSF, located on the Campus Point by Alexandria Megacampus in our University Town Center submarket.
 - The tenant currently occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and development of the new purpose-built life science building at this site. Upon delivery of the new build-to-suit property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity which will service the entire Megacampus.

Industry and corporate responsibility leadership: catalyzing and leading the way for positive change to benefit human health and society

- 8 Davis Drive on the Alexandria Center® for Advanced Technologies Research Triangle Megacampus won the prestigious 2025 BOMA (Building Owners and Managers Association) International TOBY (The Outstanding Building of the Year) Award in the Life Science category. The TOBY Awards are the commercial real estate industry's highest recognition honoring excellence in building management and operations. The award represents the company's first win in the International TOBY Awards. Of the four regional winners in the Life Science category that progressed as international TOBY nominees, three were Alexandria-owned, -operated, and -developed facilities. The two additional Alexandria facilities were:
 - 201 Haskins Way on the Alexandria Center® for Life Science South San Francisco campus in the San Francisco Bay Area and
 - 188 East Blaine Street on the Alexandria Center® for Life Science Eastlake Megacampus in Seattle.
- We released our 2024 Corporate Responsibility Report, which underscores our groundbreaking sustainability approach and the continued execution of our impactful corporate responsibility platform. Notable highlights in the report include:
 - The continued advancement of our innovative strategy to reduce operational greenhouse gas (GHG) emissions in our asset base through energy efficiency, electrification and alternative energy, and renewable electricity. We reduced operational GHG emissions intensity by 18% from 2022 to 2024, representing ongoing progress toward our 30% reduction target by 2030 relative to a 2022 baseline.
 - Our steadfast work to catalyze the health and vitality of our local communities and make a
 tangible positive impact through action-oriented solutions addressing some of the nation's
 most pressing issues, including mental health and education.
- 15 Necco Street, a state-of-the-art R&D facility totaling 345,996 RSF in our Seaport Innovation District submarket in Greater Boston, earned LEED Platinum certification, the highest certification level under the U.S. Green Building Council's Core and Shell rating system. Home to the Lilly Seaport Innovation Center, the facility serves as the central hub for Lilly's genetic medicines efforts.
- We deepened our commitment to driving educational opportunities for students and supporting STEM education with the opening of the Alexandria Real Estate Equities, Inc. Learning Lab at the Fred Hutch Cancer Center in Seattle. Designed and built by Alexandria in close collaboration with Fred Hutch's Science Education and Facilities teams, the innovative laboratory environment is dedicated to inspiring and training future scientists.

Second Quarter Ended June 30, 2025 Financial and Operating Results (continued)

June 30, 2025



Industry and corporate responsibility leadership (continued)

- Alexandria was named a recipient of the 2025 Charles A. Sanders, MD, Partnership Award by
 the Foundation for the National Institutes of Health (FNIH) in recognition of our key role in
 catalyzing a public-private partnership focused on the development of biomarkers for major
 depressive disorder to address the urgent need for new medicines for neuropsychology.
- Lawrence J. Diamond, co-chief operating officer and regional market director of Maryland, was honored with the Beacon of Service Award at the Maryland Tech Council's 2025 ICON Awards. The award recognizes Mr. Diamond's leadership, service, and profound impact on Maryland's innovation ecosystem and broader community.

About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500[®] company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2025, Alexandria has a total market capitalization of \$25.7 billion and an asset base in North America that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction and one 100% pre-leased committed near-term project expected to commence construction in the next year. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Guidance

June 30, 2025

(Dollars in millions, except per share amounts)



Guidance for 2025 has been updated to reflect our current view of existing market conditions and assumptions for the year ending December 31, 2025. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. Our guidance for 2025 is subject to a number of variables and uncertainties, including actions and changes in policy by the current U.S. administration related to the regulatory environment, life science funding, the U.S. Food and Drug Administration and National Institutes of Health, trade, and other areas. For additional discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated, refer to our discussion of "forward-looking statements" on page 7 of the Earnings Press Release as well as our SEC filings, including our most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q.

	2025 Guidance Midpoint		2025 (Guidan	ce Midpo	oint
Summary of Key Changes in Guidance	As of 7/21/25 As of 4/28/2	Summary of Key Changes in Sources and Uses of Capital	As of 7/2	21/25	As of 4/	/28/25
EPS. FFO per share, and FFO per share, as adjusted	See updates below	Repayment of secured note payable ⁽⁵⁾	\$	154	\$	

Projected 2025 Earnings per Share and Funds From Operations per Share Attributable to Alexandria's Common Stockholders – Diluted

	As of 7/21/25	As of 4/28/25
Earnings per share ⁽¹⁾	\$0.40 to \$0.60	\$1.36 to \$1.56
Depreciation and amortization of real estate assets	7.05	7.05
Gain on sales of real estate	(80.0)	(80.0)
Impairment of real estate – rental properties and land ⁽²⁾	0.77	0.21
Allocation to unvested restricted stock awards	(0.03)	(0.03)
Funds from operations per share and funds from operations per share, as adjusted ⁽³⁾	\$8.11 to \$8.31	\$8.51 to \$8.71
Unrealized losses on non-real estate investments	0.53	0.40
Impairment of non-real estate investments ⁽²⁾	0.30	0.07
Impairment of real estate	0.23	0.19
Allocation to unvested restricted stock awards	(0.01)	(0.01)
Funds from operations per share, as adjusted ⁽³⁾	\$9.16 to \$9.36	\$9.16 to \$9.36
Midpoint	\$9.26	\$9.26

Maponi		Ψ0.20		
Key Assumptions		Low		High
Occupancy percentage in North America as of December 31, 2025		90.9%		92.5%
Lease renewals and re-leasing of space:				
Rental rate changes		9.0%		17.0%
Rental rate changes (cash basis)		0.5%		8.5%
Same property performance:				
Net operating income		(3.7)%		(1.7)%
Net operating income (cash basis)		(1.2)%		0.8%
Straight-line rent revenue		\$ 96	\$	116
General and administrative expenses		\$ 112	\$	127
Capitalization of interest		\$ 320	\$	350
Interest expense		\$ 185	\$	215
Realized gains on non-real estate investments ⁽⁴⁾		\$ 100	\$	130

Key Credit Metric Targets⁽³⁾

Net debt and preferred stock to Adjusted EBITDA – 4Q25 annualized	Less than or equal to 5.2x
Fixed-charge coverage ratio – 4Q25 annualized	4.0x to 4.5x

Rar	nge		Mi	idpoint	Completed Items		
\$ (290)	\$	(290)	\$	(290)	S	ee below	
425		525		475			
1,450		2,450		1,950		(6)	
\$ 1,585	\$	2,685	\$	2,135			
\$ 1,450	\$	2,050	\$	1,750			
_		500		250	\$	208 (7)	
135		135		135	\$	135	
\$ 1,585	\$	2,685	\$	2,135			
			_				
\$ 550	\$	550	\$	550	\$	550	
(600)		(600)		(600)	\$	(600)	
(154)		(154)		(154)			
(86)		(86)		(86)			
\$ (290)	\$	(290)	\$	(290)			
\$ \$	\$ (290) 425 1,450 \$ 1,585 \$ 1,450 	\$ (290) \$ 425 1,450 \$ 1,585 \$ 1,450 \$ 135 \$ 1,585 \$ 1,585 \$ (600) (154) (86)	425 525 1,450 2,450 \$ 1,585 \$ 2,685 \$ 1,450 \$ 2,050 — 500 135 135 \$ 1,585 \$ 2,685 \$ 550 \$ 550 (600) (600) (154) (154) (86) (86)	\$ (290) \$ (290) \$ 425	\$ (290) \$ (290) \$ (290) 425 525 475 1,450 2,450 1,950 \$ 1,585 \$ 2,685 \$ 2,135 \$ 1,450 \$ 2,050 \$ 1,750 500 250 135 135 135 \$ 1,585 \$ 2,685 \$ 2,135 \$ 550 \$ 550 \$ 550 (600) (600) (154) (154) (154) (86) (86) (86)	Range Midpoint \$ (290) \$ (290) \$ (290) \$ 425 525 475 1,450 2,450 1,950 \$ 1,585 \$ 2,685 \$ 2,135 \$ 1,450 \$ 2,050 \$ 1,750 — 500 250 \$ 135 \$ 1,585 \$ 2,685 \$ 2,135 \$ 550 \$ 550 \$ 550 \$ 600 (600) (600) (600) \$ (600) (154) (154) (154) (154) (86) (86) (86) (86)	

- (1) Excludes unrealized gains or losses on non-real estate investments after June 30, 2025 that are required to be recognized in earnings and are excluded from funds from operations per share, as adjusted.
- (2) Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release for additional details.
- (3) Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.
- (4) Represents realized gains and losses included in funds from operations per share diluted, as adjusted, and excludes significant impairments realized on non-real estate investments, if any. Refer to "Investments" in the Supplemental Information for additional details.
- (5) In August 2025, we expect to repay a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, a development project where we have a 76.9% interest. Refer to "Key capital events" in the Earnings Press release for additional details.
- (6) As of July 21, 2025, completed dispositions aggregated \$260.6 million and our share of pending transactions subject to non-refundable deposits, signed letters of intent, or purchase and sale agreement negotiations aggregated \$524.7 million. We expect to achieve a weighted-average capitalization rate on our projected 2025 dispositions and partial interest sales (excluding land and including stabilized and non-stabilized operating properties) in the 7.5% 8.5% range. We expect dispositions of land to represent 20%–30% of our total dispositions and sales of partial interest sales for the year ending December 31, 2025. Refer to "Dispositions and sales of partial interests" in the Earnings Press Release for additional details.
- (7) Under our common stock repurchase program authorized in December 2024, we may repurchase up to \$500.0 million of our common stock through December 31, 2025. During 2Q25, we did not repurchase any shares of common stock. As of July 21, 2025, the approximate value of shares authorized and remaining under this program was \$241.8 million. Subject to market conditions, we may consider repurchasing additional shares of our common stock.

Certain

Dispositions and Sales of Partial Interests

June 30, 2025

(Dollars in thousands)



				Square	Footage		Gain on	
Property	Submarket/Market	Date of Sale	Interest Sold	Operating	Future Development	Sales Price	Sa	ales of al Estate
Completed in 1Q25						\$ 176,352	\$	13,165
Completed in 2Q25:								
Properties with vacancies								
2425 Garcia Avenue and 2400/2450 Bayshore Parkway	Greater Stanford/San Francisco Bay Area	6/30/25	100%	95,901	_	11,000		_
Land								
Land parcel	Texas	5/7/25	100%	_	1,350,000	73,287		
						84,287		
Dispositions completed in 1H25						260,639	\$	13,165
Our share of pending dispositions and sales of partial interests subject to								
non-refundable deposits, signed letters of intent, and/or purchase and sale agreement negotiations						524,745		
Our share of completed and pending 2025 dispositions and sales of partial interests						\$ 785,384		
2025 guidance range for dispositions and sales of partial interests					\$1,450,00	00 – \$2,450,000		
2025 guidance midpoint for dispositions and sales of partial interests						\$ 1,950,000		

Earnings Call Information and About the Company





We will host a conference call on Tuesday, July 22, 2025, at 2:00 p.m. Eastern Time ("ET")/11:00 a.m. Pacific Time ("PT"), which is open to the general public, to discuss our financial and operating results for the second quarter ended June 30, 2025. To participate in this conference call, dial (833) 366-1125 or (412) 902-6738 shortly before 2:00 p.m. ET/11:00 a.m. PT and ask the operator to join the call for Alexandria Real Estate Equities, Inc. The audio webcast can be accessed at www.are.com in the "For Investors" section. A replay of the call will be available for a limited time from 4:00 p.m. ET/1:00 p.m. PT on Tuesday, July 22, 2025. The replay number is (877) 344-7529 or (412) 317-0088, and the access code is 1006663.

Additionally, a copy of this Earnings Press Release and Supplemental Information for the second quarter ended June 30, 2025 is available in the "For Investors" section of our website at www.are.com or by following this link: https://www.are.com/fs/2025q2.pdf.

For any questions, please contact corporateinformation@are.com; Joel S. Marcus, executive chairman and founder; Peter M. Moglia, chief executive officer and chief investment officer; Marc E. Binda, chief financial officer and treasurer; or Paula Schwartz, managing director of Rx Communications Group, at (917) 633-7790.

About the Company

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500[®] company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2025, Alexandria has a total market capitalization of \$25.7 billion and an asset base in North America that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction and one 100% pre-leased committed near-term project expected to commence construction in the next year. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements

This document includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our projected 2025 earnings per share, projected 2025 funds from operations per share per share, as adjusted, projected net operating income, and our projected sources and uses of capital. You can identify the forward-looking statements by their use of forward-looking words, such as "forecast," "guidance," "goals," "projects," "estimates," "anticipates," "believes," "expects," "intends," "may," "plans," "seeks," "should," "targets," or "will," or the negative of those words or similar words. These forward-looking statements are based on our current expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts, as well as a number of assumptions concerning future events. There can be no assurance that actual results will not be materially higher or lower than these expectations. These statements are subject to risks, uncertainties, assumptions, and other important factors that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that might cause such a difference include, without limitation, our failure to obtain capital (debt. construction financing, and/or equity) or refinance debt maturities, lower than expected yields, increased interest rates and operating costs, adverse economic or real estate developments in our markets, our failure to successfully place into service and lease any properties undergoing development or redevelopment and our existing space held for future development or redevelopment (including new properties acquired for that purpose), our failure to successfully operate or lease acquired properties, decreased rental rates, increased vacancy rates or failure to renew or replace expiring leases, defaults on or non-renewal of leases by tenants, adverse general and local economic conditions, an unfavorable capital market environment, decreased leasing activity or lease renewals, failure to obtain LEED and other healthy building certifications and efficiencies, and other risks and uncertainties detailed in our filings with the Securities and Exchange Commission ("SEC"). Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are made as of the date of this Earnings Press Release and Supplemental Information, and unless otherwise stated, we assume no obligation to update this information and expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in our forward-looking statements, and risks to our business in general, please refer to our SEC filings, including our most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q.

This document is not an offer to sell or a solicitation to buy securities of Alexandria Real Estate Equities, Inc. Any offers to sell or solicitations to buy our securities shall be made only by means of a prospectus approved for that purpose. Unless otherwise indicated, the "Company," "Alexandria," "ARE," "we," "us," and "our" refer to Alexandria Real Estate Equities, Inc. and our consolidated subsidiaries. Alexandria®, Lighthouse Design® logo, Building the Future of Life-Changing Innovation®, That's What's in Our DNA®, Megacampus™, At the Vanguard and Heart of the Life Science Ecosystem™, Alexandria Center®, Alexandria Technology Square®, Alexandria Technology Center®, and Alexandria Innovation Center® are copyrights and trademarks of Alexandria Real Estate Equities, Inc. All other company names, trademarks, and logos referenced herein are the property of their respective owners.

Consolidated Statements of Operations

June 30, 2025

(Dollars in thousands, except per share amounts)



			Th	ree N	Months Ende	ed				nded		
	6/30/25		3/31/25	1	12/31/24		9/30/24	6/30/24		6/30/25		6/30/24
Revenues:												
Income from rentals	\$ 737,279	\$	743,175	\$	763,249	\$	775,744	\$ 755,162	\$	1,480,454	\$	1,510,713
Other income	24,761		14,983		25,696		15,863	11,572		39,744		25,129
Total revenues	762,040		758,158		788,945		791,607	766,734		1,520,198		1,535,842
Expenses:												
Rental operations	224,433		226,395		240,432		233,265	217,254		450,828		435,568
General and administrative	29,128		30,675		32,730		43,945	44,629		59,803		91,684
Interest	55,296		50,876		55,659		43,550	45,789		106,172		86,629
Depreciation and amortization	346,123		342,062		330,108		293,998	290,720		688,185		578,274
Impairment of real estate	 129,606		32,154		186,564		5,741	30,763		161,760		30,763
Total expenses	784,586		682,162		845,493		620,499	629,155		1,466,748		1,222,918
Equity in (losses) earnings of unconsolidated real estate joint ventures	(9,021) ⁽¹)	(507)		6,635		139	130		(9,528)		285
Investment (loss) income	(30,622)		(49,992)		(67,988)		15,242	(43,660)		(80,614)		(376)
Gain on sales of real estate	 		13,165		101,806		27,114			13,165		392
Net (loss) income	(62,189)		38,662		(16,095)		213,603	94,049		(23,527)		313,225
Net income attributable to noncontrolling interests	(44,813)		(47,601)		(46,150)		(45,656)	(47,347)		(92,414)		(95,978)
Net (loss) income attributable to Alexandria Real Estate Equities, Inc.'s stockholders	(107,002)		(8,939)		(62,245)		167,947	46,702		(115,941)		217,247
Net income attributable to unvested restricted stock awards	 (2,609)		(2,660)		(2,677)		(3,273)	(3,785)		(5,269)		(7,444)
Net (loss) income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders	\$ (109,611)	\$	(11,599)	\$	(64,922)	\$	164,674	\$ 42,917	\$	(121,210)	\$	209,803
Net (loss) income per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders:												
Basic	\$ (0.64)	\$	(0.07)	\$	(0.38)	\$	0.96	\$ 0.25	\$	(0.71)	\$	1.22
Diluted	\$ (0.64)	\$	(0.07)	\$	(0.38)	\$	0.96	\$ 0.25	\$	(0.71)	\$	1.22
Weighted-average shares of common stock outstanding:												
Basic	170,135		170,522		172,262		172,058	172,013		170,328		171,981
Diluted	170,135		170,522		172,262		172,058	172,013		170,328		171,981
Dividends declared per share of common stock	\$ 1.32	\$	1.32	\$	1.32	\$	1.30	\$ 1.30	\$	2.64	\$	2.57

⁽¹⁾ Refer to footnote 1 in "Funds from operations and funds from operations per share" in the Earnings Press Release for additional details.

Consolidated Balance Sheets

June 30, 2025 (In thousands)



	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24
Assets					
Investments in real estate	\$ 32,160,600	\$ 32,121,712	\$ 32,110,039	\$ 32,951,777	\$ 32,673,839
Investments in unconsolidated real estate joint ventures	40,234	50,086	39,873	40,170	40,535
Cash and cash equivalents	520,545	476,430	552,146	562,606	561,021
Restricted cash	7,403	7,324	7,701	17,031	4,832
Tenant receivables	6,267	6,875	6,409	6,980	6,822
Deferred rent	1,232,719	1,210,584	1,187,031	1,216,176	1,190,336
Deferred leasing costs	491,074	489,287	485,959	516,872	519,629
Investments	1,476,696	1,479,688	1,476,985	1,519,327	1,494,348
Other assets	1,688,091	1,758,442	1,661,306	1,657,189	1,356,503
Total assets	\$ 37,623,629	\$ 37,600,428	\$ 37,527,449	\$ 38,488,128	\$ 37,847,865
Liabilities, Noncontrolling Interests, and Equity					
	\$ 153,500	\$ 150,807	\$ 149,909	\$ 145,000	\$ 134,942
Secured notes payable	12,042,607	12,640,144			,
Unsecured senior notes payable Unsecured senior line of credit and commercial paper		299,883	12,094,465	12,092,012 454,589	12,089,561
• •	1,097,993	2,281,414	2 654 251	2,865,886	199,552
Accounts payable, accrued expenses, and other liabilities	2,360,840 229,686	2,261,414	2,654,351 230,263	2,005,000	2,529,535
Dividends payable Total liabilities	15,884,626				227,408
Total liabilities	15,884,020	15,600,870	15,128,988	15,784,678	15,180,998
Commitments and contingencies					
Redeemable noncontrolling interests	9,612	9,612	19,972	16,510	16,440
Alexandria Real Estate Equities, Inc.'s stockholders' equity:					
Common stock	1,701	1,701	1,722	1,722	1,720
Additional paid-in capital	17,200,949	17,509,148	17,933,572	18,238,438	18,284,611
Accumulated other comprehensive loss	(27,415)	(46,202)	(46,252)	(22,529)	(27,710)
Alexandria Real Estate Equities, Inc.'s stockholders' equity	17,175,235	17,464,647	17,889,042	18,217,631	18,258,621
Noncontrolling interests	4,554,156	4,525,299	4,489,447	4,469,309	4,391,806
Total equity	21,729,391	21,989,946	22,378,489	22,686,940	22,650,427
Total liabilities, noncontrolling interests, and equity	\$ 37,623,629	\$ 37,600,428	\$ 37,527,449	\$ 38,488,128	\$ 37,847,865

Funds From Operations and Funds From Operations per Share

June 30, 2025

(In thousands)



The following table presents a reconciliation of net income (loss) attributable to Alexandria's common stockholders, the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP"), including our share of amounts from consolidated and unconsolidated real estate joint ventures, to funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted, for the periods below:

		Th		Six Month	ns Ended		
	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24	6/30/25	6/30/24
Net (loss) income attributable to Alexandria's common stockholders – basic and diluted	\$ (109,611)	\$ (11,599)	\$ (64,922)	\$ 164,674	\$ 42,917	\$ (121,210)	\$ 209,803
Depreciation and amortization of real estate assets	343,729	339,381	327,198	291,258	288,118	683,110	573,068
Noncontrolling share of depreciation and amortization from consolidated real estate JVs	(36,047)	(33,411)	(34,986)	(32,457)	(31,364)	(69,458)	(62,268)
Our share of depreciation and amortization from unconsolidated real estate JVs	942	1,054	1,061	1,075	1,068	1,996	2,102
Gain on sales of real estate	_	(13,165)	(100,109)	(27,114)	_	(13,165)	(392)
Impairment of real estate – rental properties and land	131,090 ⁽¹⁾	_	184,532	5,741	2,182	131,090	2,182
Allocation to unvested restricted stock awards	(1,222)	(686)	(1,182)	(2,908)	(1,305)	(1,916)	(4,736)
Funds from operations attributable to Alexandria's common stockholders – diluted ⁽²⁾	328,881	281,574	311,592	400,269	301,616	610,447	719,759
Unrealized losses (gains) on non-real estate investments	21,938	68,145	79,776	(2,610)	64,238	90,083	35,080
Impairment of non-real estate investments	39,216 ⁽³⁾	11,180	20,266	10,338	12,788	50,396	27,486
Impairment of real estate	7,189	32,154	2,032	_	28,581	39,343	28,581
Increase (decrease) in provision for expected credit losses on financial instruments	_	285	(434)	_	_	285	_
Allocation to unvested restricted stock awards	(794)	(1,329)	(1,407)	(125)	(1,738)	(2,116)	(1,528)
Funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted	\$ 396,430	\$ 392,009	\$ 411,825	\$ 407,872	\$ 405,485	\$ 788,438	\$ 809,378

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ Primarily represents impairment charges to reduce the carrying amount of our investments in real estate assets to their respective estimated fair values less costs to sell upon their classification as held for sale in 2Q25, including (i) \$47.5 million related to land parcels in our non-cluster market, (ii) \$35.4 million related to an office property located in Carlsbad, San Diego, and (iii) \$8.7 million related to an unconsolidated real estate joint venture, which is classified in equity in earnings of unconsolidated real estate joint ventures in our consolidated statement of operations.

⁽²⁾ Calculated in accordance with standards established by the Nareit Board of Governors.

⁽³⁾ Primarily related to one non-real estate investment in a privately held entity that does not report NAV.

Funds From Operations and Funds From Operations per Share (continued)

June 30, 2025

(In thousands, except per share amounts)



The following table presents a reconciliation of net income (loss) per share attributable to Alexandria's common stockholders, the most directly comparable financial measure presented in accordance with GAAP, including our share of amounts from consolidated and unconsolidated real estate joint ventures, to funds from operations per share attributable to Alexandria's common stockholders – diluted, and funds from operations per share attributable to Alexandria's common stockholders – diluted, as adjusted, for the periods below. Per share amounts may not add due to rounding.

				Thi	ree Mo	onths End	led					Six Montl	ths Ended		
	6/	30/25	3/	31/25	12	/31/24	9/30/24		6/30/24		6/30/25		6/	/30/24	
Net (loss) income per share attributable to Alexandria's common stockholders – diluted	\$	(0.64)	\$	(0.07)	\$	(0.38)	\$	0.96	\$	0.25	\$	(0.71)	\$	1.22	
Depreciation and amortization of real estate assets		1.81		1.80		1.70		1.51		1.50		3.61		2.98	
Gain on sales of real estate		_		(80.0)		(0.58)		(0.16)		_		(80.0)		_	
Impairment of real estate – rental properties and land		0.77		_		1.07		0.03		0.01		0.77		0.01	
Allocation to unvested restricted stock awards		(0.01)						(0.01)		(0.01)		(0.01)		(0.02)	
Funds from operations per share attributable to Alexandria's common stockholders – diluted		1.93		1.65		1.81		2.33		1.75		3.58		4.19	
Unrealized losses (gains) on non-real estate investments		0.13		0.40		0.46		(0.02)		0.37		0.53		0.20	
Impairment of non-real estate investments		0.23		0.07		0.12		0.06		0.08		0.30		0.16	
Impairment of real estate		0.04		0.19		0.01		_		0.17		0.23		0.17	
Allocation to unvested restricted stock awards				(0.01)		(0.01)				(0.01)		(0.01)		(0.01)	
Funds from operations per share attributable to Alexandria's common stockholders – diluted, as adjusted	\$	2.33	\$	2.30	\$	2.39	\$	2.37	\$	2.36	\$	4.63	\$	4.71	
Weighted-average shares of common stock outstanding – diluted															
Earnings per share – diluted	1	170,135	1	170,522	1	172,262	1	72,058	1	72,013	1	70,328	1	171,981	
Funds from operations – diluted, per share	170,192		1	170,599	172,262		172,058		172,013		170,390		171,981		
Funds from operations – diluted, as adjusted, per share	1	170,192	1	170,599	1	172,262	1	72,058	1	72,013	1	70,390	1	171,981	

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

SUPPLEMENTAL INFORMATION



Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500[®] company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2025, Alexandria has a total market capitalization of \$25.7 billion and an asset base in North America that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction and one 100% pre-leased committed near-term project expected to commence construction in the next year. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Tenant base

Alexandria is known for our high-quality and diverse tenant base, with 53% of our annual rental revenue being generated from tenants that are investment-grade rated or publicly traded large cap companies. The quality, diversity, breadth, and depth of our significant relationships with our tenants provide Alexandria with high-quality and stable cash flows. Alexandria's underwriting team and long-term industry relationships positively distinguish us from all other publicly traded REITs and real estate companies.

Executive and senior management team

Alexandria's executive and senior management team has unique experience and expertise in creating, owning, and operating highly dynamic and collaborative Megacampus real estate in key life science cluster locations to catalyze innovation. From design to development to the management of our high-quality, sustainable real estate, as well as our ongoing cultivation of collaborative environments with unique amenities and events, the Alexandria team has a best-in-class reputation of excellence in life science real estate. Alexandria's highly experienced management team includes regional market directors with leading reputations and long-standing relationships within the life science communities in their respective innovation clusters. We believe that our experience, expertise, reputation, and key relationships in the real estate and life science industries provide Alexandria significant competitive advantages in attracting new business opportunities.

Alexandria's executive and senior management team consists of 62 individuals, averaging 24 years of real estate experience, including 13 years with Alexandria. Our executive management team alone averages 19 years with Alexandria.

EXECUTIVE MANAGEMENT TEAM

Joel S. Marcus

Executive Chairman & Founder

Daniel J. Ryan

Co-President & Regional Market Director – San Diego

Marc E. Binda

Chief Financial Officer & Treasurer

Joseph Hakman

Co-Chief Operating Officer & Chief Strategic Transactions Officer

Jackie B. Clem

General Counsel & Secretary

Andres R. Gavinet

Chief Accounting Officer

Kristina A. Fukuzaki-Carlson

Executive Vice President – Business Operations

Peter M. Moglia

Chief Executive Officer & Chief Investment Officer

Hunter L. Kass

Co-President & Regional Market Director – Greater Boston

Lawrence J. Diamond

Co-Chief Operating Officer & Regional Market Director – Maryland

Hart Cole

Executive Vice President – Capital Markets/Strategic Operations & Co-Regional Market Director – Seattle

Gary D. Dean

Executive Vice President – Real Estate Legal Affairs

Onn C. Lee

Executive Vice President – Accounting

Madeleine T. Alsbrook

Executive Vice President – Talent Management

Investor Information

June 30, 2025



Corporate Headquarters

New York Stock Exchange Trading Symbol

Information Requests

26 North Euclid Avenue

Pasadena, California 91101

Common stock: ARE

(626) 578-0777 Email: corporateinformation@are.com

www.are.com

Website: investor.are.com

Phone:

Equity Research Coverage

Alexandria is currently covered by the following research analysts. This list may be incomplete and is subject to change as firms initiate or discontinue coverage of our company. Please note that any opinions, estimates, or forecasts regarding our historical or predicted performance made by these analysts are theirs alone and do not represent opinions, estimates, or forecasts of Alexandria or our management. Alexandria does not by our reference or distribution of the information below imply our endorsement of or concurrence with any opinions, estimates, or forecasts of these analysts. Interested persons may obtain copies of analysts' reports on their own as we do not distribute these reports. Several of these firms may, from time to time, own our stock and/or hold other long or short positions in our stock and may provide compensated services to us.

_	 _	_		_	
					1e

Nate Crossett / Monir Koummal (646) 342-1588 / (646) 342-1554

BofA Securities

Jeff Spector / Farrell Granath (646) 855-1363 / (646) 855-1351

BTIG, LLC

Tom Catherwood / Michael Tompkins (212) 738-6140 / (212) 527-3566

CFRA

Nathan Schmidt (646) 517-1144

Citigroup Global Markets Inc.

Nicholas Joseph / Seth Bergey (212) 816-1909 / (212) 816-2066

Citizens

Aaron Hecht / Linda Fu (415) 835-3963 / (415) 869-4411

Deutsche Bank AG

Tayo Okusanya / Samuel Ohiomah (212) 250-9284 / (212) 250-0057

Evercore ISI

Steve Sakwa / James Kammert (212) 446-9462 / (312) 705-4233

Green Street

Dylan Burzinski (949) 640-8780

J.P. Morgan Securities LLC

Anthony Paolone / Ray Zhong (212) 622-6682 / (212) 622-5411

Jefferies

Peter Abramowitz / Katie Elders (212) 336-7241 / (917) 421-1968

Mizuho Securities USA LLC

Vikram Malhotra / Georgi Dinkov (212) 282-3827 / (617) 352-1721

RBC Capital Markets

Michael Carroll (440) 715-2649

Robert W. Baird & Co. Incorporated

Wesley Golladay / Nicholas Thillman (216) 737-7510 / (414) 298-5053

Fixed Income Research Coverage

Barclays Capital Inc.

Srinjoy Banerjee / Japheth Otieno (212) 526-3521 / (212) 526-6961

Mizuho Securities USA LLC

Thierry Perrein (212) 205-7665

J.P. Morgan Securities LLC

Mark Streeter (212) 834-5086

Rating Agencies

Moody's Ratings **S&P Global Ratings** (212) 553-0376 Alan Zigman (416) 507-2556

Financial and Asset Base Highlights

June 30, 2025

(Dollars in thousands, except per share amounts)



	Three Months Ended (unless stated otherwise)									
	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24					
Selected financial data from consolidated financial statements and related information										
Rental revenues	\$ 553,377	\$ 552,112	\$ 566,535	\$ 579,569	\$ 576,835					
Tenant recoveries	\$ 183,902	\$ 191,063	\$ 196,714	\$ 196,175	\$ 178,327					
General and administrative expenses	\$ 29,128	\$ 30,675	\$ 32,730	\$ 43,945	\$ 44,629					
General and administrative expenses as a percentage of net operating income – trailing 12 months	6.3%	6.9%	7.6%	8.9%	9.2%					
Operating margin	71%	70%	70%	71%	72%					
Adjusted EBITDA margin	71%	71%	72%	70%	72%					
Adjusted EBITDA – quarter annualized	\$ 2,174,160	\$ 2,165,632	\$ 2,273,480	\$ 2,219,632	\$ 2,216,144					
Adjusted EBITDA – trailing 12 months	\$ 2,208,226	\$ 2,218,722	\$ 2,228,921	\$ 2,184,298	\$ 2,122,250					
Net debt at end of period	\$ 12,844,726	\$ 12,687,856	\$ 11,762,176	\$ 12,191,574	\$11,940,144					
Net debt and preferred stock to Adjusted EBITDA – quarter annualized	5.9x	5.9x	5.2x	5.5x	5.4x					
Net debt and preferred stock to Adjusted EBITDA – trailing 12 months	5.8x	5.7x	5.3x	5.6x	5.6x					
Total debt and preferred stock at end of period	\$ 13,294,100	\$ 13,090,834	\$ 12,244,374	\$ 12,691,601	\$12,424,055					
Gross assets at end of period	\$ 43,770,007	\$ 43,486,989	\$ 43,152,628	\$ 44,112,770	\$43,305,279					
Total debt and preferred stock to gross assets at end of period	30%	30%	28%	29%	29%					
Fixed-charge coverage ratio – quarter annualized	4.1x	4.3x	4.3x	4.4x	4.5x					
Fixed-charge coverage ratio – trailing 12 months	4.3x	4.4x	4.5x	4.5x	4.6x					
Unencumbered net operating income as a percentage of total net operating income	99.7%	99.8%	99.9%	99.1%	99.1%					
Closing stock price at end of period	\$ 72.63	\$ 92.51	\$ 97.55	\$ 118.75	\$ 116.97					
Common shares outstanding (in thousands) at end of period	170,146	170,130	172,203	172,244	172,018					
Total equity capitalization at end of period	\$ 12,357,709	\$ 15,738,715	\$ 16,798,446	\$ 20,454,023	\$20,120,907					
Total market capitalization at end of period	\$ 25,651,809	\$ 28,829,549	\$ 29,042,820	\$ 33,145,624	\$32,544,962					
Dividend per share – quarter/annualized	\$1.32/\$5.28	\$1.32/\$5.28	\$1.32/\$5.28	\$1.30/\$5.20	\$1.30/\$5.20					
Dividend payout ratio for the quarter	57%	57%	55%	55%	55%					
Dividend yield – annualized	7.3%	5.7%	5.4%	4.4%	4.4%					
Amounts related to operating leases:										
Operating lease liabilities at end of period	\$ 363,419	\$ 371,412	\$ 507,127	\$ 648,338	\$ 379,223					
Rent expense	\$ 12,139	\$ 11,666	\$ 10,685	\$ 10,180	\$ 9,412					
None expense		,	ψ 10,000	ψ 10,100	ψ 3,712					
Capitalized interest	\$ 82,423		\$ 81,586	\$ 86,496	\$ 81,039					
Average real estate basis capitalized during the period	\$ 8,107,180	\$ 8,026,566	\$ 8,118,010	\$ 8,281,318	\$ 7,936,612					
Weighted-average interest rate for capitalization of interest during the period	4.07%	3.99%	4.02%	3.98%	3.96%					

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ Increase in capitalized interest driven primarily by an increase in the weighted-average interest rate from 3.99% at 1Q25 to 4.07% at 2Q25.

Financial and Asset Base Highlights (continued)

June 30, 2025

(Dollars in thousands, except annual rental revenue per occupied RSF amounts)



		therwise)								
		6/30/25		3/31/25		12/31/24		9/30/24		6/30/24
Amounts included in funds from operations and non-revenue-enhancing capital expenditures										
Straight-line rent revenue	\$	18,536	\$	22,023	\$	17,653	\$	29,087	\$	48,338
Amortization of acquired below-market leases	\$	10,196	\$	15,222	\$	15,512	\$	17,312	\$	22,515
Amortization of deferred revenue related to tenant-funded and -built landlord improvements	\$	2,401	\$	1,651	\$	1,214	\$	329	\$	_
Straight-line rent expense on ground leases	\$	87	\$	149	\$	1,021	\$	789	\$	341
Cash payment for ground lease extension	\$	_	\$	(135,000)	\$	(135,000)	\$	_	\$	_
Stock compensation expense	\$	12,530	\$	10,064	\$	12,477	\$	15,525	\$	14,507
Amortization of loan fees	\$	4,615	\$	4,691	\$	4,620	\$	4,222	\$	4,146
Amortization of debt discounts	\$	335	\$	349	\$	333	\$	330	\$	328
Non-revenue-enhancing capital expenditures:										
Building improvements	\$	4,622	\$	3,789	\$	4,313	\$	4,270	\$	4,210
Tenant improvements and leasing commissions	\$	23,971	\$	73,483	\$	81,918	\$	55,920	\$	15,724
Funds from operations attributable to noncontrolling interests	\$	80,860	\$	81,012	\$	76,111	\$	78,113	\$	78,711
Operating statistics and related information (at end of period)										
Number of properties – North America		384		386		391		406		408
RSF – North America (including development and redevelopment projects under construction)	4	3,699,922		43,687,343	44,124,001		46,748,734		4	7,085,993
Total square footage – North America	6	7,220,337		68,518,184		69,289,411		73,611,815	7	4,103,404
Annual rental revenue per occupied RSF – North America	\$	58.68	\$	58.38	\$	56.98	\$	57.09	\$	56.87
Occupancy of operating properties – North America		90.8%	(1)	91.7%		94.6%		94.7%		94.6%
Occupancy of operating and redevelopment properties – North America		86.2%		86.9%		89.7%		89.7%		89.9%
Weighted-average remaining lease term (in years)		7.4		7.6		7.5		7.5		7.4
Total leasing activity – RSF		769,815	(2)	1,030,553		1,310,999		1,486,097		1,114,001
Lease renewals and re-leasing of space – change in average new rental rates over expiring rates:										
Rental rate changes		5.5%		18.5%		18.1%		5.1%		7.4%
Rental rate changes (cash basis)		6.1%		7.5%		3.3%		1.5%		3.7%
RSF (included in total leasing activity above)		483,409		884,408		1,024,862		1,278,857		589,650
Top 20 tenants:										
Annual rental revenue	\$	795,244	\$	754,354	\$	741,965	\$	796,898	\$	805,751
Annual rental revenue from investment-grade or publicly traded large cap tenants		89%		87%		92%		92%		92%
Weighted-average remaining lease term (in years)		9.4		9.6		9.3		9.5		9.4
Same property – percentage change over comparable quarter from prior year:										
Net operating income changes		(5.4)%		(3.1)%		0.6%		1.5%		1.5%
Net operating income changes (cash basis)		2.0%	(3)	5.1%		6.3%		6.5%		3.9%

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.


⁽¹⁾ Refer to page 2 in the Earnings Press Release and "Summary of properties and occupancy" in the Supplemental Information for additional details.

⁽²⁾ In July 2025, we executed the largest life science lease in company history with a long-standing multinational pharmaceutical tenant for a 16-year expansion build-to-suit lease, aggregating 466,598 RSF, located on the Campus Point by Alexandria Megacampus in our University Town Center submarket. If this were included in the leasing volume for 2Q25, the total leased RSF would have increased to 1.2 million RSF for 2Q25 from 769,815 RSF.

⁽³⁾ Refer to page 2 in the Earnings Press Release and "Same property performance" in the Supplemental Information for additional details.



Stable Cash Flows From Our High-Quality and Diverse Mix of Approximately 750 Tenants



Investment-Grade or Publicly Traded Large Cap Tenants

89%

of ARE's Top 20 Tenant Annual Rental Revenue

53%

of ARE's Total Annual Rental Revenue


Percentage of ARE's Annual Rental Revenue

As of June 30, 2025. Annual rental revenue represents amounts in effect as of June 30, 2025. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures.

- (1) 79% of our annual rental revenue from biomedical institutions is from investment-grade or publicly traded large cap tenants.
- (2) 63% of our annual rental revenue from advanced technology tenants is from investment-grade or publicly traded large cap tenants.
- (3) Represents the percentage of our annual rental revenue generated by professional services, finance, telecommunications, construction/real estate companies, and retail-related tenants.



Strong, Broad, and Diverse Life Science Tenant Base Drives Solid Leasing and Long-Term Remaining Lease Terms



Long-Duration Life Science Lease Terms

	Remaining Lease Term (in years) ⁽¹⁾
Multinational Pharmaceutical	7.1
Life Science Product, Service, and Device	6.6
Government Institutions	5.1
Biomedical Institutions	7.8
Private Biotechnology	7.2
Public Biotechnology	7.1


Percentage of Life Science Leasing Activity by RSF⁽²⁾

⁽¹⁾ Average remaining lease term based on annual rental revenue in effect as of June 30, 2025.

⁽²⁾ Represents the percentage of RSF for leases executed during the three months ended June 30, 2025 for each respective business type.



Sustained Operational Excellence and Strength in Tenant Collections



99.9%

2Q25

99.4%

July 2025

99.8%

Average Tenant Collections 1Q21–2Q25

Tenant Rents And Receivables Collected⁽¹⁾

(1) Represents tenant collections for each quarter-end as of each respective earnings release date.







Margins⁽²⁾

71%

Operating

Adjusted EBITDA

71%

Long-Duration Lease Terms⁽⁴⁾

9.4 Years 7.4 Years

Top 20 Tenants

All Tenants

Rental Rate Growth: Renewed/Re-Leased Space



Favorable Lease Structure⁽³⁾

Strategic Lease Structure by Owner and **Operator of Collaborative Megacampus Ecosystems**

Increasing cash flows

Percentage of leases containing 97% annual rent escalations

Stable cash flows

Percentage of triple net leases 91%

Lower capex burden

Percentage of leases providing for the 92% recapture of capital expenditures

Refer to "Same property performance" and "Definitions and reconciliations" in the Supplemental Information for additional details. "Definitions and reconciliations" contains the definition of "Net operating income" and its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

Refer to footnote 1 under "Same property performance" in the Supplemental Information for additional details.

- For the three months ended June 30, 2025. (2)
- Percentages calculated based on our annual rental revenue in effect as of June 30, 2025.
- Represents the weighted-average remaining term based on annual rental revenue in effect as of June 30, 2025.

Same Property Performance

June 30, 2025

(Dollars in thousands)



		June 30, 2025										June	30, 2025
Same Property Financial Data		Three	Mor		Mon Ende		Same Propert	v Sta	atistical Dat	a	T	hree Months Ended	Six Months Ended
Percentage change over comparable period from prior year:							Number of sam				_	330	329
Net operating income changes ⁽¹⁾			(5.4))%	(4.3	3)%	Rentable squa	re fe	et			33,904,941	33,709,506
Net operating income changes (cash basis) ⁽¹⁾⁽²⁾		2.0%			3.	4%	Occupancy – current-period average					91.3%	92.5%
Operating margin			68	3%	% 68% C			ame	-period prior		94.5%	94.4%	
			Thr	ree Months I	Ended	d June 30,				Six Months En	nded	d June 30,	
	20)25		2024	\$	Change	% Change		2025	2024	\$	Change	% Change
Income from rentals:													
Same properties		62,622	\$	480,547	\$	(17,925)	(3.7)%	\$	925,636	\$ 950,433	\$	(24,797)	(2.6)%
Non-same properties		90,755		96,288		(5,533)	(5.7)		179,853	207,802		(27,949)	(13.4)
Rental revenues	55	53,377		576,835		(23,458)	(4.1)		1,105,489	1,158,235		(52,746)	(4.6)
Same properties	16	66,465		155,157		11,308	7.3		335,349	308,553		26,796	8.7
Non-same properties	1	17,437		23,170		(5,733)	(24.7)		39,616	43,925		(4,309)	(9.8)
Tenant recoveries	18	83,902		178,327		5,575	3.1		374,965	352,478		22,487	6.4
Income from rentals	73	37,279	_	755,162		(17,883)	(2.4)		1,480,454	1,510,713		(30,259)	(2.0)
Same properties		429		379		50	13.2		774	719		55	7.6
Non-same properties	2	24,332		11,193		13,139	117.4		38,970	24,410		14,560	59.6
Other income		24,761		11,572		13,189	114.0	_	39,744	25,129		14,615	58.2
Same properties	62	29,516		636,083		(6,567)	(1.0)		1,261,759	1,259,705		2,054	0.2
Non-same properties	13	32,524		130,651		1,873	1.4		258,439	276,137		(17,698)	(6.4)
Total revenues	76	62,040		766,734		(4,694)	(0.6)		1,520,198	1,535,842		(15,644)	(1.0)
Same properties	20	01,305		183,582		17,723	9.7		403,337	362,407		40,930	11.3
Non-same properties	2	23,128		33,672		(10,544)	(31.3)		47,491	73,161		(25,670)	(35.1)
Rental operations	22	24,433		217,254		7,179	3.3		450,828	435,568		15,260	3.5
Same properties	42	28,211		452,501		(24,290)	(5.4)		858,422	897,298		(38,876)	(4.3)
Non-same properties	10	09,396		96,979		12,417	12.8		210,948	202,976		7,972	3.9
Net operating income	\$ 53	37,607	\$	549,480	\$	(11,873)	(2.2)% (3	\$	1,069,370	\$ 1,100,274	\$	(30,904)	(2.8)% (3)
Net operating income – same properties	\$ 42	28,211	\$	452,501	\$	(24,290)	(5.4)%	\$	858,422	\$ 897,298	\$	(38,876)	(4.3)%
Straight-line rent revenue		(8,463)		(38,585)		30,122	(78.1)		(13,930)	(76,294)		62,364	(81.7)
Amortization of acquired below-market leases		(9,199)		(11,349)		2,150	(18.9)		(19,097)	(22,772)		3,675	(16.1)
Net operating income – same properties (cash basis)	\$ 41	10,549	\$	402,567	\$	7,982	2.0%	\$	825,395	\$ 798,232	\$	27,163	3.4%

Refer to "Same property comparisons" under "Definitions and reconciliations" in the Supplemental Information for additional details, including a reconciliation of same properties to total properties. "Definitions and reconciliations" also contains definitions of "Tenant recoveries" and "Net operating income" and their respective reconciliations from the most directly comparable financial measures presented in accordance with GAAP.

⁽¹⁾ Includes 1Q25 lease expirations aggregating 768,080 RSF, that are vacant as of June 30, 2025, across six properties and four submarkets. Excluding the impact of the properties with these leases, same property net operating income changes for the three and six months ended June 30, 2025 would have been (2.1)% and 6.5% (cash basis) and (1.1)% and 7.6% (cash basis), respectively. Refer to "Summary of properties and occupancy" in the Supplemental Information for additional details.

⁽²⁾ Includes the impact of initial free rent concessions that burned off after January 1, 2024 for development and redevelopment projects that were placed into service in 2023 and accordingly are part of our same property pool for the three and six months ended June 30, 2025, including at 325 Binney Street in our Cambridge submarket, 15 Necco Street in our Seaport Innovation District submarket, and 751 Gateway Boulevard in our South San Francisco submarket. Excluding the impact of these initial free rent concessions, same property net operating income changes (cash basis) for the three and six months ended June 30, 2025 would have been (1.8)% and (0.8)%, respectively.

⁽³⁾ Decrease in total net operating income includes the impact of operating properties disposed of after January 1, 2024. Excluding these dispositions, net operating income for the three and six months ended June 30, 2025 would have increased by 4.0% and 3.2%, respectively, over the corresponding periods in 2024.

Leasing Activity

June 30, 2025 (Dollars per RSF)



	Three Months	s Ended	Six Months	Ended	Year Ended			
	June 30, 2	2025	June 30,	2025	December 31, 2024			
	Including Straight-Line Rent	Cash Basis	Including Straight-Line Rent	Cash Basis	Including Straight-Line Rent	Cash Basis		
Leasing activity:								
Renewed/re-leased space ⁽¹⁾								
Rental rate changes	5.5%	6.1%	13.2%	6.9%	16.9%	7.2%		
New rates	\$64.78	\$68.27	\$60.11	\$59.72	\$65.48	\$64.18		
Expiring rates	\$61.38	\$64.36	\$53.10	\$55.84	\$56.01	\$59.85		
RSF	483,409		1,367,817		3,888,139			
Tenant improvements/leasing commissions	\$49.59		\$80.68 (2)		\$46.89			
Weighted-average lease term	9.4 years		9.8 years		8.5 years			
Developed/redeveloped/previously vacant space lease	$d^{(3)}$							
New rates	\$58.12	\$58.73	\$55.31	\$55.61	\$59.44	\$57.34		
RSF	286,406		432,551		1,165,815			
Weighted-average lease term	12.3 years		11.5 years		10.0 years			
Leasing activity summary (totals):								
New rates	\$62.30	\$64.72	\$58.96	\$58.73	\$64.16	\$62.68		
RSF	769,815 ⁽⁴⁾		1,800,368		5,053,954			
Weighted-average lease term	10.5 years		10.2 years		8.9 years			
Lease expirations ⁽¹⁾								
Expiring rates	\$63.31	\$63.62	\$53.95	\$55.17	\$53.82	\$57.24		
RSF	825,583		2,748,631		5,005,638			

Leasing activity includes 100% of results for properties in North America in which we have an investment.

⁽¹⁾ Excludes month-to-month leases aggregating 163,493 RSF and 136,131 RSF as of June 30, 2025 and December 31, 2024, respectively. During the trailing twelve months ended June 30, 2025, we granted free rent concessions averaging 0.9 months per annum.

⁽²⁾ Includes tenant improvements and leasing commissions for one 11.4-year lease, executed during the three months ended March 31, 2025, at the Alexandria Technology Square® Megacampus in our Cambridge submarket aggregating 119,280 RSF. Excluding this lease, tenant improvements and leasing commissions per RSF for the six months ended June 30, 2025 was \$47.01.

⁽³⁾ Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" in the Supplemental Information for additional details, including total project costs.

⁽⁴⁾ In July 2025, we executed the largest life science lease in company history with a long-standing multinational pharmaceutical tenant for a 16-year expansion build-to-suit lease, aggregating 466,598 RSF, located on the Campus Point by Alexandria Megacampus in our University Town Center submarket. If this were included in the leasing volume for 2Q25, the total leased RSF would have increased to 1.2 million RSF for 2Q25 from 769,815 RSF.



Year RSF		Percentage of Occupied RSF	ental Revenue r RSF) ⁽¹⁾	Percentage of Annual Rental Revenue		
2025 (2)	1,320,692	3.7%	\$ 51.73	3.3%		
2026	3,137,647	8.9%	\$ 57.29	8.8%		
2027	3,393,561	9.6%	\$ 50.88	8.4%		
2028	4,015,759	11.4%	\$ 50.83	10.0%		
2029	2,286,491	6.5%	\$ 48.02	5.4%		
2030	3,078,313	8.7%	\$ 43.50	6.5%		
2031	3,585,208	10.2%	\$ 54.35	9.5%		
2032	993,042	2.8%	\$ 57.50	2.8%		
2033	2,592,303	7.3%	\$ 47.59	6.0%		
2034	3,063,408	8.7%	\$ 68.56	10.2%		
Thereafter	7,838,957	22.2%	\$ 76.19	29.1%		

2025 Contractual Lease Expirations (in RSF)

2026 Contractual Lease Expirations (in RSF)

Market	Leased	Negotiating/ Anticipating	Targeted for Future Development/ Redevelopment ⁽³⁾	Remaining Expiring Leases ⁽⁴⁾	Total ⁽²⁾	Annual Rental Revenue (per RSF) ⁽¹⁾	Leased	Negotiating/ Anticipating	Targeted for Future Development/ Redevelopment	Remaining Expiring Leases ⁽⁴⁾	Total	Annual Rental Revenue (per RSF) ⁽¹⁾
Greater Boston	214,399	_		145,329	359,728	\$ 35.89	60,418	11,897	_	514,566	586,881	\$ 89.16
San Francisco Bay Area	134,423	10,208	_	279,182	423,813	95.48	28,454	_	_	686,304	714,758	72.57
San Diego	23,327	_	_	68,081	91,408	55.21	_	_	_	846,084	846,084	48.90
Seattle	1,868	_	_	54,781	56,649	32.64	29,604	50,552	_	111,720	191,876	30.42
Maryland	41,283	_	_	23,469	64,752	22.61	_	_	_	255,147	255,147	18.85
Research Triangle	10,478	8,368	_	34,461	53,307	43.56	19,753	_	_	159,362	179,115	39.19
New York City	_	_	_	30,384	30,384	96.62	_	_	_	73,363	73,363	103.16
Texas	_	_	198,972	_	198,972	N/A	_	_	_	_	_	_
Canada	_	_	_	40,679	40,679	10.65	_	247,743	_	1,755	249,498	21.57
Non-cluster/other markets				1,000	1,000	N/A		9,266		31,659	40,925	85.36
Total	425,778	18,576	198,972	677,366	1,320,692	\$ 51.73	138,229	319,458		2,679,960	3,137,647	\$ 57.29
Percentage of expiring leases	32%	1%	15%	52%	100%		4%	10%	0%	86%	100%	

Contractual lease expirations for properties classified as held for sale as of June 30, 2025 are excluded from the information on this page.

- (1) Represents amounts in effect as of June 30, 2025.
- (2) Excludes month-to-month leases aggregating 163,493 RSF as of June 30, 2025.
- 3) Primarily represents assets that were recently acquired for future development or redevelopment opportunities, for which we expect, subject to market conditions and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development. As of June 30, 2025, the weighted-average annual rental revenue and expiration date of these leases expiring in 2025 is \$895 thousand and July 1, 2025, respectively. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- 4) Includes 12 properties primarily located in Greater Boston, the San Francisco Bay Area, and San Diego markets aggregating 868,289 RSF with a weighted-average lease expiration date of February 9, 2026 and annual rental revenue aggregating \$70 million and are expected to be re-leased to new tenants, including the following:
 - (i) Three properties aggregating 213,705 RSF in our Greater Stanford submarket that were recently acquired and we are evaluating options to reposition the campus for advanced technology use;
 - (ii) One property aggregating 118,225 RSF in our Torrey Pines submarket for which we are evaluating options to re-lease or reposition the space from single tenancy to multi-tenancy; and
 - (iii) One lease expiration aggregating 34,714 RSF at our Alexandria Technology Square Megacampus in our Cambridge submarket for which we are in the process of repositioning the building for multi-tenant use.

We continue to evaluate the business plans and re-leasing strategies for these projects.



Investment-Grade

89% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade or Publicly Traded Large Cap Tenants⁽¹⁾

		Remaining Lease		Annual Rental	Percentage of Annual Rental	Credit R		Average arket Cap
	Tenant	Term ⁽¹⁾ (in years)	Aggregate RSF	Revenue ⁽¹⁾	Revenue ⁽¹⁾	Moody's	S&P	billions)
1	Bristol-Myers Squibb Company ⁽²⁾	5.8	1,312,184	\$ 113,542	5.5%	A2	Α	\$ 106.0
2	Eli Lilly and Company	9.3	1,086,165	91,233	4.4	Aa3	A+	\$ 791.0
3	Moderna, Inc.	10.9	496,814	88,729	4.3	_	_	\$ 19.5
4	Takeda Pharmaceutical Company Limited	9.9	549,759	47,899	2.3	Baa1	BBB+	\$ 45.0
5	AstraZeneca PLC	6.4	450,848	39,637	1.9	A1	A+	\$ 227.0
6	Eikon Therapeutics, Inc. (3)	13.5	311,806	38,913	1.9	_	_	\$ _
7	Roche	7.7	647,069	36,373	1.7	Aa2	AA	\$ 255.0
8	Illumina, Inc.	5.4	857,967	35,924	1.7	Baa3	BBB	\$ 18.1
9	Alphabet Inc.	2.3	625,015	34,899	1.7	Aa2	AA+	\$ 2,120.0
10	United States Government	5.1	429,359	29,502 (4)	1.4	Aaa	AA+	\$ _
11	Uber Technologies, Inc.	57.3 ⁽⁵⁾	1,009,188	27,809	1.3	Baa1	BBB	\$ 155.0
12	Novartis AG	3.1	387,563	27,709	1.3	Aa3	AA-	\$ 238.0
13	Cloud Software Group, Inc.	1.0 (6)	292,013	26,446	1.3	_	_	\$ _
14	Boston Children's Hospital	11.7	309,231	26,294	1.3	Aa2	AA	\$ _
15	The Regents of the University of California	9.9	363,974	25,309	1.2	Aa2	AA	\$ _
16	Sanofi	5.5	267,278	21,851	1.0	Aa3	AA	\$ 132.0
17	New York University	7.1	218,983	21,110	1.0	Aa2	AA-	\$ _
18	Merck & Co., Inc.	8.2	333,124	21,001	1.0	Aa3	A+	\$ 250.0
19	Charles River Laboratories, Inc.	10.0	250,905	20,535	1.0	_	_	\$ 8.9
20	Massachusetts Institute of Technology	4.5	242,428	20,529	1.0	Aaa	AAA	\$ _
	Total/weighted-average	9.4 (5)	10,441,673	\$ 795,244	38.2%			

Annual rental revenue and RSF include 100% of each property managed by us in North America. Refer to "Annual rental revenue" and "Investment-grade or publicly traded large cap tenants" under "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures and average market capitalization, respectively.

- Based on annual rental revenue in effect as of June 30, 2025.
- (2) During the three months ended June 30, 2025, Bristol-Myers Squibb Company acquired 2seventy bio, Inc., which was a Top 20 tenant as of March 31, 2025.
- 3) Eikon Therapeutics, Inc. is a private biotechnology company led by renowned biopharma executive Roger Perlmutter, formerly an executive vice president at Merck & Co., Inc. As of February 25, 2025, the company has raised over \$1.2 billion in private venture capital funding.
- (4) Includes leases, which are not subject to annual appropriations, with governmental entities such as the National Institutes of Health and the General Services Administration. Approximately 3% of the annual rental revenue derived from our leases with the United States Government is cancellable prior to the lease expiration date.
- (5) Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual rental revenue is presented using 100% of the annual rental revenue from our unconsolidated real estate joint ventures. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 7.6 years as of June 30, 2025.
- (6) Represents one lease encompassing four properties acquired in 2022 that we expect to reposition upon lease expiration. This lease with Cloud Software Group, Inc. (formerly known as TIBCO Software, Inc.) was in place when we acquired the properties. Refer to footnote 4 in "Contractual lease expirations" in the Supplemental Information for additional details.



Solid Historical Occupancy of 95% Over Past 10 Years⁽¹⁾ From Historically Strong Demand for Our Class A/A+ Properties in AAA Locations

Summary of properties

		RSF						Annual Rental Revenue				
Market	Operating	Development	Redevelopment	Total	% of Total	Number of Properties		Total	% of Total	Per RSF		
Greater Boston	9,270,787	632,850	1,626,322	11,529,959	26%	65	\$	731,510	35%	\$	87.55	
San Francisco Bay Area	7,991,106	212,796	344,934	8,548,836	20	64		459,269	22		69.82	
San Diego	6,851,449	784,590	_	7,636,039	17	74		324,236	16		49.91	
Seattle	3,178,090	227,577	_	3,405,667	8	45		130,470	6		45.45	
Maryland	3,848,923	_	_	3,848,923	9	50		155,975	7		43.70	
Research Triangle	3,825,870	_	_	3,825,870	9	38		107,155	5		30.19	
New York City	921,800	_	_	921,800	2	4		75,006	4		91.48	
Texas	1,845,159	_	73,298	1,918,457	4	15		37,761	2		24.93	
Canada	979,575	_	56,314	1,035,889	2	11		20,208	1		22.74	
Non-cluster/other markets	349,099	_	_	349,099	1	10		14,577	1		57.54	
Properties held for sale	679,383	_	_	679,383	2	8		25,063	1		43.66	
North America	39,741,241	1,857,813	2,100,868	43,699,922	100%	384	\$	2,081,230	100%	\$	58.68	
		3,95	58,681									

Summary of occupancy

	Ope	erating Properties		Operating and Redevelopment Properties				
Market	6/30/25	3/31/25	6/30/24	6/30/25	3/31/25	6/30/24		
Greater Boston	90.1% (2)	91.8%	94.2%	76.7%	78.4%	81.7%		
San Francisco Bay Area	88.9 (2)	90.3	94.0	85.2	86.3	90.7		
San Diego	94.8	94.3	95.1	94.8	94.3	95.1		
Seattle	90.3	91.5	94.7	90.3	91.5	93.7		
Maryland	93.9	94.1	96.5	93.9	94.1	96.5		
Research Triangle	92.8 (2)	93.4	97.4	92.8	93.4	97.4		
New York City	88.9 (3)	87.6	85.1	88.9	87.6	85.1		
Texas	82.1 (2)	82.1	95.5	78.9	78.9	91.8		
Subtotal	91.0	91.8	94.7	86.3	87.1	90.2		
Canada	90.7	94.6	94.9	85.8	82.4	82.5		
Non-cluster/other markets	72.6	73.0	75.6	72.6	73.0	75.6		
North America	90.8% (2)(4)	91.7%	94.6%	86.2%	86.9%	89.9%		

⁽¹⁾ Represents the average occupancy percentage of operating properties as of each December 31 from 2016 through 2024 and as of June 30, 2025.

⁽²⁾ Includes previously disclosed lease expirations that became vacant in 1Q25 aggregating 768,080 RSF across six properties and in four submarkets comprising the following: (i) 182,054 RSF at the Alexandria Technology Square® Megacampus in our Cambridge submarket, (ii) 234,249 RSF at 409 Illinois Street in our Mission Bay submarket, (iii) one property aggregating 104,531 RSF in our Research Triangle market, and (iv) two properties aggregating 247,246 RSF in our Austin submarket. As of June 30, 2025, 153,658 RSF was leased with a weighted-average lease commencement date of April 30, 2026, and we expect to favorably resolve the remaining 614,422 RSF over the next several quarters.

⁽³⁾ The Alexandria Center® for Life Science – New York City Megacampus is 97.8% occupied as of June 30, 2025. Occupancy percentage in our New York City market reflects vacancy at the Alexandria Center® for Life Science – Long Island City property, which was 52.2% occupied as of June 30, 2025.

⁽⁴⁾ Includes temporary vacancies as of June 30, 2025 aggregating 668,795 RSF, or 1.7%, primarily in the Greater Boston, San Francisco Bay Area, and San Diego markets, which are leased and expected to be occupied upon completion of building and/or tenant improvements. The weighted-average expected delivery date is January 2, 2026.



Our Megacampus[™] Properties Account for 75% of Our Annual Rental Revenue

					Annual	Occupancy Percentage			
			RSF		Number of	Rental		Operating and	
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment	
Greater Boston									
Cambridge/Inner Suburbs									
Megacampus: Alexandria Center [®] at Kendall Square	2,213,867	_	_	2,213,867	8	\$ 211,592	97.4%	97.4%	
50 ⁽¹⁾ , 60 ⁽¹⁾ , 75/125 ⁽¹⁾ , 90, 100 ⁽¹⁾ , and 225 ⁽¹⁾ Binney Street, 140 First Street, and 300 Third Street ⁽¹⁾									
Megacampus: Alexandria Center [®] at One Kendall Square	1,284,337	_	104,956	1,389,293	12	144,417	94.2	87.1	
One Kendall Square (Buildings 100, 200, 300, 400, 500, 600/700, 1400, 1800, and 2000), 325 and 399 Binney Street, and One Hampshire Street									
Megacampus: Alexandria Technology Square® 100, 200, 300, 400, 500, 600, and 700 Technology Square	1,190,888	_	_	1,190,888	7	96,651	79.5	79.5	
Megacampus: The Arsenal on the Charles	751,316	36,444	333,758	1,121,518	13	45,819	79.6	55.1	
311, 321, and 343 Arsenal Street, 300, 400, and 500 North Beacon Street, 1, 2, 3, and 4 Kingsbury Avenue, and 100, 200, and 400 Talcott Avenue									
Megacampus: 480 Arsenal Way, 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue ⁽¹⁾	623,056	204,395	_	827,451	6	27,508	95.9	95.9	
Cambridge/Inner Suburbs	6,063,464	240,839	438,714	6,743,017	46	525,987	90.9	84.7	
Fenway									
Megacampus: Alexandria Center® for Life Science – Fenway 401 and 421 Park Drive and 201 Brookline Avenue	1,295,745	392,011	137,675	1,825,431	3	99,477	87.2	78.8	
Seaport Innovation District					_				
5 and 15 ⁽¹⁾ Necco Street	459,395			459,395	2	47,345	96.6	96.6	
Seaport Innovation District	459,395	_	_	459,395	2	47,345	96.6	96.6	
Route 128	400.004		500.004	4 000 450	_	00.744	400.0	40.0	
Megacampus: Alexandria Center® for Life Science – Waltham 40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street	466,094	_	596,064	1,062,158	5	39,741	100.0	43.9	
19, 225, and 235 Presidential Way	585.226	_	_	585.226	3	14.194	97.0	97.0	
Route 128	1,051,320		596,064	1,647,384	8	53,935	98.3	62.8	
Other	400,863	_	453,869	854,732	6	4,766	59.7	28.0	
Greater Boston	9,270,787	632,850	1,626,322	11,529,959	65	\$ 731,510	90.1%	76.7%	

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2025

(Dollars in thousands)



						Annual	Occupancy Percentage		
			SF		Number of	Rental		Operating and	
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment	
San Francisco Bay Area									
Mission Bay									
Megacampus: Alexandria Center [®] for Science and Technology – Mission Bay ⁽¹⁾	2,023,185	212,796 ⁽³	_	2,235,981	10	\$ 78,852	82.5%	82.5%	
1455 ⁽²⁾ , 1515 ⁽²⁾ , 1655, and 1725 Third Street, 409 and 499 Illinois Street, 1450 ⁽³⁾ , 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South									
Mission Bay	2,023,185	212,796		2,235,981	10	78,852	82.5	82.5	
South San Francisco									
Megacampus: Alexandria Technology Center® – Gateway ⁽¹⁾ 600 ⁽²⁾ , 601, 611, 630 ⁽²⁾ , 650 ⁽²⁾ , 651, 681, 685, 701, 751, 901 ⁽²⁾ , and 951 ⁽²⁾ Gateway Boulevard	1,431,608	_	237,684	1,669,292	12	76,715	81.3	69.7	
Megacampus: Alexandria Center [®] for Advanced Technologies – South San Francisco	812,453	_	107,250	919,703	5	52,990	100.0	88.3	
213 ⁽¹⁾ , 249, 259, 269, and 279 East Grand Avenue									
Alexandria Center [®] for Life Science – South San Francisco 201 Haskins Way and 400 and 450 East Jamie Court	504,235	_	_	504,235	3	32,001	88.0	88.0	
Megacampus: Alexandria Center® for Advanced Technologies – Tanforan	445,232	_	_	445,232	2	2,359	100.0	100.0	
1122 and 1150 El Camino Real									
Alexandria Center [®] for Life Science – Millbrae ⁽¹⁾ 230 Harriet Tubman Way	285,346	_	_	285,346	1	35,828	100.0	100.0	
500 Forbes Boulevard ⁽¹⁾	155,685	_	_	155,685	1	10,908	100.0	100.0	
South San Francisco	3,634,559		344,934	3,979,493	24	210,801	91.0	83.1	
Greater Stanford									
Megacampus: Alexandria Center® for Life Science – San Carlos 825, 835, 960, and 1501-1599 Industrial Road	738,038	_	_	738,038	9	44,886	88.1	88.1	
Alexandria Stanford Life Science District	704,716	_	_	704,716	9	72,225	97.0	97.0	
3160, 3165, 3170, and 3181 Porter Drive and 3301, 3303, 3305, 3307, and 3330 Hillview Avenue									
3412, 3420, 3440, 3450, and 3460 Hillview Avenue	340,103	_	_	340,103	5	23,597	82.9	82.9	
3875 Fabian Way	228,000	_	_	228,000	1	9,642	100.0	100.0	
2475 and 2625/2627/2631 Hanover Street and 1450 Page Mill Road	198,548	_	_	198,548	3	12,893	89.4	89.4	
2100 and 2200 Geng Road	62,526	_	_	62,526	2	2,732	100.0	100.0	
3350 West Bayshore Road	61,431			61,431	1	3,641	73.2	73.2	
Greater Stanford	2,333,362			2,333,362	30	169,616	91.2	91.2	
San Francisco Bay Area	7,991,106	212,796	344,934	8,548,836	64	\$ 459,269	88.9%	85.2%	

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

⁽²⁾ We own 100% of this property.

⁽³⁾ Represents a multi-tenant project expanding the Alexandria Center® for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF to our presentation of the development project.

June 30, 2025

(Dollars in thousands)



						Annual	Occupancy Percentage		
Market / Submarket / Address	Operating	Development	RSF Redevelopment	Total	Number of Properties	Rental Revenue	Operating	Operating and Redevelopment	
	Operating	Development	Redevelopment	Total	Порениез	Revenue	Operating	Redevelopment	
San Diego									
Torrey Pines	060 507	400 200		1 000 000	10	\$ 62.077	00.00/	88.2%	
Megacampus: One Alexandria Square 3115 and 3215 ⁽¹⁾ Merryfield Row, 3010, 3013, and 3033 Science Park Road, 10935, 10945, 10955, and 10970 Alexandria Way, 10996 Torreyana Road, and 3545 Cray Court	968,527	122,302	_	1,090,829	10	\$ 62,077	88.2%	00.2%	
ARE Torrey Ridge	299,138	_	_	299,138	3	13,263	79.7	79.7	
10578, 10618, and 10628 Science Center Drive									
ARE Nautilus	218,459	_	_	218,459	4	14,656	97.7	97.7	
3530 and 3550 John Hopkins Court and 3535 and 3565 General Atomics Court									
Torrey Pines	1,486,124	122,302	_	1,608,426	17	89,996	87.9	87.9	
University Town Center									
Megacampus: Campus Point by Alexandria ⁽¹⁾	1,310,696	426,927	_	1,737,623	8	81,788	98.8	98.8	
9880 ⁽²⁾ , 10210, 10290, and 10300 Campus Point Drive and 4135, 4155, 4224, and 4242 Campus Point Court									
Megacampus: 5200 Illumina Way ⁽¹⁾	792,687	_	_	792,687	6	29,978	100.0	100.0	
9625 Towne Centre Drive ⁽¹⁾	163,648			163,648	1	6,520	100.0	100.0	
University Town Center	2,267,031	426,927		2,693,958	15	118,286	99.3	99.3	
Sorrento Mesa									
Megacampus: SD Tech by Alexandria ⁽¹⁾	816,048	235,361	_	1,051,409	11	37,003	96.0	96.0	
9605, 9645, 9675, 9725, 9735, 9808, 9855, and 9868 Scranton Road, and 10055, 10065, and 10075 Barnes Canyon Road									
Megacampus: Sequence District by Alexandria	671,039	_	_	671,039	6	23,458	100.0	100.0	
6290, 6310, 6340, 6350, 6420, and 6450 Sequence Drive									
Pacific Technology Park ⁽¹⁾	544,352	_	_	544,352	5	9,352	92.8	92.8	
9389, 9393, 9401, 9455, and 9477 Waples Street									
Summers Ridge Science Park ⁽¹⁾	316,531	_	_	316,531	4	11,521	100.0	100.0	
9965, 9975, 9985, and 9995 Summers Ridge Road									
Scripps Science Park by Alexandria	144,113	_	_	144,113	1	11,379	100.0	100.0	
10102 Hoyt Park Drive	404.057			404.057	0	4.000	100.0	400.0	
ARE Portola	101,857	_	_	101,857	3	4,222	100.0	100.0	
6175, 6225, and 6275 Nancy Ridge Drive	83,354			83,354	1	4,621	100.0	100.0	
5810/5820 Nancy Ridge Drive 9877 Waples Street	63,774	_	_	63,774	1	2,680	100.0	100.0	
5871 Oberlin Drive	33,842	_	<u>_</u>	33,842	1	2,103	100.0	100.0	
Sorrento Mesa	2,774,910	235,361		3,010,271	33	106,339	97.4	97.4	
Sorrento Valley	2,774,910	233,301	_	3,010,271	33	100,339	97.4	97.4	
3911, 3931, 3985, 4025, 4031, and 4045 Sorrento Valley Boulevard	151,406		_	151,406	6	2,866	42.7	42.7	
11045 and 11055 Roselle Street	43,233	_	_	43,233	2	2,191	96.3	96.3	
Sorrento Valley	194,639			194,639	8	5,057	54.6	54.6	
Other	128.745		_	128,745	1	4,558	100.0	100.0	
San Diego	6,851,449	784,590		7,636,039	74	\$ 324,236	94.8%	94.8%	
oan biego	0,051,445	104,530	_	1,030,039	7-7	Ψ JZ4,ZJU	34.0 /0	J-1.0 /0	

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

⁽²⁾ We own 100% of this property.

June 30, 2025

(Dollars in thousands)



						Annual	Occupan	ncy Percentage
		F	RSF		Number of	Rental		Operating and
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment
Seattle								
Lake Union								
Megacampus: Alexandria Center® for Life Science – Eastlake	1,151,672	_	_	1,151,672	9	\$ 73,275	93.8%	93.8%
1150, 1201 ⁽¹⁾ , 1208 ⁽¹⁾ , 1551, 1600, and 1616 Eastlake Avenue East, 188 and 199 ⁽¹⁾ East Blaine Street, and 1600 Fairview Avenue East								
Megacampus: Alexandria Center [®] for Advanced Technologies – South Lake Union	381,380	227,577	_	608,957	3	21,811	99.6	99.6
400 ⁽¹⁾ and 701 Dexter Avenue North and 428 Westlake Avenue North								
219 Terry Avenue North	31,797	_	_	31,797	1	1,368	56.9	56.9
Lake Union	1,564,849	227,577		1,792,426	13	96,454	94.5	94.5
Elliott Bay								
410 West Harrison Street and 410 Elliott Avenue West	20,101	_	_	20,101	2	710	100.0	100.0
Bothell								
Megacampus: Alexandria Center [®] for Advanced Technologies – Canyon Park	1,065,194	_	_	1,065,194	22	21,113	86.3	86.3
22121 and 22125 17th Avenue Southeast, 22021, 22025, 22026, 22030, 22118, and 22122 20th Avenue Southeast, 22333, 22422, 22515, 22522, 22722, and 22745 29th Drive Southeast, 21540, 22213 and 22309 30th Drive Southeast, and 1629, 1631, 1725, 1916, and 1930 220th Street Southeast								
Alexandria Center [®] for Advanced Technologies – Monte Villa Parkway 3301, 3303, 3305, 3307, 3555, and 3755 Monte Villa Parkway	464,889	_	_	464,889	6	11,527	83.9	83.9
Bothell	1,530,083			1,530,083	28	32,640	85.6	85.6
Other	63,057	_	_	63,057	2	666	100.0	100.0
Seattle	3,178,090	227,577		3,405,667	45	130,470	90.3	90.3
Maryland Rockville								
Megacampus: Alexandria Center® for Life Science – Shady Grove	1.691.960	_	_	1,691,960	20	92,343	94.4	94.4
9601, 9603, 9605, 9704, 9708, 9712, 9714, 9800, 9804, 9808, 9900, and 9950 Medical Center Drive, 14920 and 15010 Broschart Road, 9920 Belward Campus Drive, and 9810 and 9820 Darnestown Road	, ,			,,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
1330 Piccard Drive	131,508	_	_	131,508	1	4,324	100.0	100.0
1405 and 1450 ⁽¹⁾ Research Boulevard	114,182	_	_	114,182	2	2,958	72.8	72.8
1500 and 1550 East Gude Drive	91,359	_	_	91,359	2	1,844	100.0	100.0
5 Research Place	63,852	_	_	63,852	1	3,108	100.0	100.0
5 Research Court	51,520	_	_	51,520	1	1,976	100.0	100.0
12301 Parklawn Drive	49,185			49,185	1	1,598	100.0	100.0
Rockville	2,193,566			2,193,566	28	\$ 108,151	94.3 %	94.3 %

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2025

(Dollars in thousands)



						Annual	Occupan	cy Percentage
		l	RSF		Number of	Rental		Operating and
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment
Maryland (continued)								
Gaithersburg								
Alexandria Technology Center® – Gaithersburg I	619,061	_	_	619,061	9	\$ 19,642	93.6 %	93.6 %
9, 25, 35, 45, 50, and 55 West Watkins Mill Road and 910, 930, and 940 Clopper Road								
Alexandria Technology Center® – Gaithersburg II	486,300	_	_	486,300	7	17,692	95.1	95.1
700, 704, and 708 Quince Orchard Road and 19, 20, 21, and 22 Firstfield Road								
20400 Century Boulevard	81,006	_	_	81,006	1	1,858	100.0	100.0
401 Professional Drive	63,207	_	_	63,207	1	1,434	82.7	82.7
950 Wind River Lane	50,000	_	_	50,000	1	1,234	100.0	100.0
620 Professional Drive	27,950			27,950	1	1,207	100.0	100.0
Gaithersburg	1,327,524	_	_	1,327,524	20	43,067	94.4	94.4
Beltsville								
8000/9000/10000 Virginia Manor Road	191,884	_	_	191,884	1	3,050	100.0	100.0
101 West Dickman Street ⁽¹⁾	135,949	_	_	135,949	1	1,707	75.0	75.0
Beltsville	327,833			327,833	2	4,757	89.6	89.6
Maryland	3,848,923			3,848,923	50	155,975	93.9	93.9
Research Triangle								
Research Triangle								
Megacampus: Alexandria Center® for Life Science – Durham	2,214,887	_	_	2,214,887	16	54,090	97.6	97.6
6, 8, 10, 12, 14, 40, 41, 42, and 65 Moore Drive, 21, 25, 27, 29, and 31 Alexandria Way, 2400 Ellis Road, and 14 TW Alexander Drive								
Megacampus: Alexandria Center [®] for Advanced Technologies and AgTech – Research Triangle	711,490	_	_	711,490	6	29,518	93.2	93.2
6, 8, 10, and 12 Davis Drive and 5 and 9 Laboratory Drive								
Megacampus: Alexandria Center® for Sustainable Technologies 104, 108, 110, 112, and 114 TW Alexander Drive and 5 and 7 Triangle Drive	364,493	_	_	364,493	7	7,283	60.7	60.7
Alexandria Technology Center® – Alston	155,731	_	_	155,731	3	2,755	82.2	82.2
100, 800, and 801 Capitola Drive								
Alexandria Innovation Center® – Research Triangle	136,722	_	_	136,722	3	4,222	98.3	98.3
7010, 7020, and 7030 Kit Creek Road								
2525 East NC Highway 54	82,996	_	_	82,996	1	3,651	100.0	100.0
407 Davis Drive	81,956	_	_	81,956	1	3,323	100.0	100.0
601 Keystone Park Drive	77,595			77,595	1	2,313	100.0	100.0
Research Triangle	3,825,870	_	_	3,825,870	38	\$ 107,155	92.8 %	92.8 %

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2025

(Dollars in thousands)



						Annual	Occupancy Percentage	
W 1 (10 / 1 (14))			RSF	T ()	Number of	Rental	0 "	Operating and
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment
New York City								
New York City								
Megacampus: Alexandria Center® for Life Science – New York City	742,700	_	_	742,700	3	\$ 69,318	97.8%	97.8%
430 and 450 East 29th Street								
Alexandria Center [®] for Life Science – Long Island City	179,100	_	_	179,100	1	5,688	52.2	52.2
30-02 48th Avenue								
New York City	921,800	_	_	921,800	4	75,006	88.9	88.9
Texas								
Austin								
Megacampus: Intersection Campus	1,525,359	_	_	1,525,359	12	33,694	83.0	83.0
507 East Howard Lane, 13011 McCallen Pass, 13813 and 13929 Center Lake Drive, and 12535, 12545, 12555, and 12565 Riata Vista Circle								
1001 Trinity Street and 1020 Red River Street	198,972	_	_	198,972	2	895	100.0	100.0
Austin	1,724,331	_		1,724,331	14	34,589	84.9	84.9
Greater Houston								
Alexandria Center® for Advanced Technologies at The Woodlands	120,828	_	73,298	194,126	1	3,172	41.5	25.8
8800 Technology Forest Place								
Texas	1,845,159		73,298	1,918,457	15	37,761	82.1	78.9
Canada	979,575	_	56,314	1,035,889	11	20,208	90.7	85.8
Non-cluster/other markets	349,099	_	_	349,099	10	14,577	72.6	72.6
North America, excluding properties held for sale	39,061,858	1,857,813	2,100,868	43,020,539	376	2,056,167	90.8%	86.2%
Properties held for sale	679,383	_	_	679,383	8	25,063	84.5%	84.5%
Total – North America	39,741,241	1,857,813	2,100,868	43,699,922	384	\$2,081,230	•	
		-,,	=, : : : , : : :				-	

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.



ALEXANDRIA'S DEVELOPMENT AND REDEVELOPMENT DELIVERIES ARE EXPECTED TO PROVIDE INCREMENTAL GROWTH IN ANNUAL NET OPERATING INCOME

Placed Into Service

1H25

\$52M⁽¹⁾

96% Occupied

527,268 RSF

Near-Term Deliveries

3Q25-4Q26

\$139M⁽²⁾

84%⁽⁴⁾ Leased/Negotiating

1.2 million RSF⁽⁵⁾

Intermediate-Term Deliveries

2027-2028

\$261M⁽³⁾

28% Leased/Negotiating

3.3 million RSF

Refer to "Net operating income" under "Definitions and reconciliations" in the Supplemental Information for additional details, including its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

⁽¹⁾ Excludes incremental annual net operating income from recently delivered spaces aggregating 22,005 RSF that are vacant and/or unleased as of June 30, 2025.

²⁾ Includes expected partial deliveries through 4Q26 from projects expected to stabilize in 2027 and beyond, including speculative future leasing that is not yet fully committed. Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 3Q25 through 4Q26 is projected to be \$103 million. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for additional details.

⁽³⁾ Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 2027 through 2028 is projected to be \$236 million.

⁽⁴⁾ Represents the leased/negotiating percentage of development and redevelopment projects that are expected to stabilize during 2H25 and 2026.

⁽⁵⁾ Represents the RSF related to projects expected to stabilize by 4Q26. Does not include RSF for partial deliveries through 4Q26 from projects expected to stabilize in 2027 and beyond.

Investments in Real Estate (continued)

June 30, 2025

(Dollars in thousands)



Investments in real estate

	_		Develo	pment and Redevelo			
		Under Con	struction	100% Pre-leased			
	Operating	2025 and 2026	2027 and Beyond	Committed Near Term ⁽¹⁾	Future	Subtotal	Total
Square footage							
Operating	39,061,858	_	_	_	_	_	39,061,858
Future Class A/A+ development and redevelopment properties	_	1,155,041	2,803,640	466,598	24,754,090	29,179,369	29,179,369
Future development and redevelopment square feet currently included in rental properties ⁽²⁾		<u> </u>	_	(52,620)	(2,525,858)	(2,578,478)	(2,578,478)
Total square footage, excluding properties held for sale	39,061,858	1,155,041	2,803,640	413,978	22,228,232	26,600,891	65,662,749
Properties held for sale	679,383	_	_	_	878,205	878,205	1,557,588
Total square footage	39,741,241	1,155,041	2,803,640	413,978	23,106,437	27,479,096	67,220,337
Investments in real estate							
Gross book value as of June 30, 2025 ⁽³⁾	\$ 29,681,626	\$ 1,128,865	\$ 2,657,516	\$ 19,965	\$ 4,819,006	\$ 8,625,352	\$ 38,306,978

Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata with our joint venture partner.

(2) Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including future development and redevelopment square feet currently included in rental properties.

⁽³⁾ Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheet. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details.



Incremental Annual Net Operating Income Generated From 1H25 Deliveries Aggregated \$52 Million, Including \$15 Million⁽¹⁾ in 2Q25

230 Harriet Tubman Way

San Francisco Bay Area/ South San Francisco 285,346 RSF 100% Occupancy

10935, 10945, and 10955 Alexandria Way⁽²⁾

San Diego/Torrey Pines 212,694 RSF 100% Occupancy

10075 Barnes Canyon Road

San Diego/Sorrento Mesa 17,718 RSF 100% Occupancy







				RSF Plac	ed in Service					Unleve	red Yields
	2Q25 Delivery	Our Ownership	Prior to				Occupancy_	Total	Project	Initial	Initial Stabilized
Property/Market/Submarket	Date ⁽³⁾	Interest	1/1/25	1Q25	2Q25	Total	Percentage ⁽⁴⁾	RSF	Investment	Stabilized	(Cash Basis)
Development projects											
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco	N/A	48.5%	_	285,346	_	285,346	100%	285,346	476,000	7.5%	6.2%
10935, 10945, and 10955 Alexandria Way/San Diego/ Torrey Pines	5/11/25	100%	93,492	_	119,202	212,694	100%	334,996	480,000 (5)	7.2	6.9
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	N/A	50.0%	_	17,718	_	17,718	100%	253,079	321,000	5.5	5.7
Redevelopment projects											
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	N/A ⁽⁶⁾	50.0%	67,017	_	22,005 (6)	89,022	75% (6)	326,706	487,000	5.0	5.1
Canada	5/29/25	100%	78,487	6,430	76,567	161,484	100%	250,790	115,000	6.0	6.0
Weighted average/total	5/14/25	· !	238,996	309,494	217,774	766,264		1,450,917	\$ 1,879,000	6.3%	6.0%

Refer to "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for additional details on the square footage in service and under construction, if applicable.

- (1) Excludes incremental annual net operating income from recently delivered spaces aggregating 22,005 RSF that are vacant and/or unleased as of June 30, 2025. Refer to footnote 6 below.
- 2) Image represents 10955 Alexandria Way on the One Alexandria Square Megacampus.
- 3) Represents the average delivery date for deliveries that occurred during the current quarter, weighted by annual rental revenue.
- (4) Occupancy relates to total operating RSF placed in service as of the most recent delivery.
- (5) Improvements of 100 bps and 110 bps in initial stabilized yield and initial stabilized yield (cash basis), respectively, were primarily driven by leasing space at higher rental rates than previously underwritten and a \$23 million reduction in total investment due to construction cost savings from overall project efficiencies.
- (6) Represents a turnkey space delivered vacant and unleased that did not generate incremental annual net operating income as of June 30, 2025.



99 Coolidge Avenue

Greater Boston/ Cambridge/Inner Suburbs 204,395 RSF

76% Leased/Negotiating



Greater Boston/ Cambridge/Inner Suburbs

36,444 RSF

92% Leased/Negotiating



San Diego/Torrey Pines

122,302 RSF

100% Leased







4135 Campus Point Court

San Diego/ University Town Center 426,927 RSF

100% Leased

10075 Barnes Canyon Road

San Diego/Sorrento Mesa

235,361 RSF

68% Leased/Negotiating

8800 Technology Forest Place

Texas/Greater Houston

73,298 RSF

41% Leased/Negotiating







- Image represents 500 North Beacon Street on The Arsenal on the Charles Megacampus.
- Image represents 10955 Alexandria Way on the One Alexandria Square Megacampus.



311 Arsenal Street

Greater Boston/ Cambridge/Inner Suburbs 333,758 RSF



Greater Boston/Fenway 392,011 RSF



Greater Boston/Fenway 137,675 RSF



Greater Boston/Route 128







1450 Owens Street

San Francisco Bay Area/ Mission Bay 212,796 RSF(2)



San Francisco Bay Area/ South San Francisco 237,684 RSF



San Francisco Bay Area/ South San Francisco 107,250 RSF

701 Dexter Avenue North

Seattle/Lake Union 227,577 RSF









- Image represents 60 Sylvan Road on the Alexandria Center® for Life Science Waltham Megacampus. The project is expected to capture demand in our Route 128 submarket.
- Image represents a multi-tenant project expanding the Alexandria Center® for Science and Technology Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF to our presentation of the development project.

New Class A/A+ Development and Redevelopment Properties: Current Projects





		S	quare Footage	9	Per	centage	Occu	pancy ⁽¹⁾
Property/Market/Submarket	Dev/Redev	In Service	CIP	Total	Leased	Leased/ Negotiating	Initial	Stabilized
Under construction								
2025 and 2026 stabilization								
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	Dev	116,414	204,395	320,809	52%	76%	4Q23	2026
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs	Dev	211,574	36,444	248,018	92	92	1Q24	2025
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines	Dev	212,694	122,302	334,996	100	100	4Q24	2025
4135 Campus Point Court/San Diego/University Town Center	Dev	_	426,927	426,927	100	100	2026	2026
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	Dev	17,718	235,361	253,079	68	68	1Q25	2026
8800 Technology Forest Place/Texas/Greater Houston	Redev	50,094	73,298	123,392	41	41	2Q23	2026
Canada	Redev	194,476	56,314	250,790	78	80	3Q23	2025
		802,970	1,155,041	1,958,011	80	84		
2027 and beyond stabilization								
One Hampshire Street/Greater Boston/Cambridge	Redev	_	104,956	104,956	_	_	2027	2028
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs	Redev	56,904	333,758	390,662	7	7	2027	2027
421 Park Drive/Greater Boston/Fenway	Dev	_	392,011	392,011	13	13	2027	2028
401 Park Drive/Greater Boston/Fenway	Redev	_	137,675	137,675	_	_	2026	2027
40, 50, and 60 Sylvan Road/Greater Boston/Route 128	Redev	_	596,064	596,064	33	33	2026	2027
Other/Greater Boston	Redev	_	453,869	453,869	_	_	2027	2027
1450 Owens Street/San Francisco Bay Area/Mission Bay ⁽²⁾	Dev	_	212,796	212,796	_	49 ⁽²⁾	2026	2027
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco ⁽³⁾	Redev	89,022	237,684	326,706	21	21	1Q24	2027
269 East Grand Avenue/San Francisco Bay Area/South San Francisco	Redev	_	107,250	107,250	_	_	2026	2027
701 Dexter Avenue North/Seattle/Lake Union	Dev		227,577	227,577	23	23	2026	2027
		145,926	2,803,640	2,949,566				
100% Pre-leased committed near-term project expected to commence construction i	n the next year							
Campus Point by Alexandria/San Diego/University Town Center ⁽⁴⁾	Dev	_	466,598	466,598	100	100	2028	2028
Total 2027 and beyond stabilization and committed near-term project		145,926	3,270,238	3,416,164	25	28		
		948,896	4,425,279	5,374,175	45%	49%		

⁽¹⁾ Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenant projects may increase in occupancy over a period of time.

⁽²⁾ Represents a multi-tenant project expanding the Alexandria Center® for Science and Technology – Mission Bay Megacampus, where we have a 25% interest. During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a long-term lease at the project instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project.

⁽³⁾ We continue to build out this project on a floor-by-floor basis. As of 2Q25, the remaining cost to complete is \$138 million, or 28% of the total cost at completion.

⁽⁴⁾ Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 55% interest. The project is fully leased to a longtime multinational pharmaceutical tenant that currently occupies two buildings within the Megacampus, one building aggregating 52,620 RSF and another building aggregating 52,853 RSF. At the end of 2025, the tenant will vacate the 52,620 RSF building to allow for the demolition and development of the new, build-to-suit life science building at this site. Upon delivery of the new purpose-built property anticipated to occur in 2028, the tenant will vacate the 52,853 RSF building to allow for the construction of an amenity which will service the entire Megacampus. We expect to fund the majority of future construction costs at the Megacampus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata with our joint venture partner.

New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)

June 30, 2025

(Dollars in thousands)



	Our			At	100°	%		Unlevered Yields		
Property/Market/Submarket	Ownership Interest	In	n Service	CIP		Cost to Complete	С	Total at completion	Initial Stabilized	Initial Stabilized (Cash Basis)
Under construction										
2025 and 2026 stabilization with 84% leased/negotiating										
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	76.9%	\$	136,692	\$ 217,195	\$	90,113	\$	444,000	6.0%	6.8%
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs	100%		376,928	45,565		4,507		427,000	6.2%	5.5%
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines	100%		258,106	218,712		3,182		480,000	7.2%	6.9%
4135 Campus Point Court/San Diego/University Town Center	55.0%		_	380,816		143,184		524,000	7.3%	6.2%
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	50.0%		16,646	205,116		99,238		321,000	5.5%	5.7%
8800 Technology Forest Place/Texas/Greater Houston	100%		60,360	46,373		5,267		112,000	6.3%	6.0%
Canada	100%		96,895	15,088		3,017		115,000	6.0%	6.0%
			945,627	1,128,865						
2027 and beyond stabilization ⁽¹⁾										
One Hampshire Street/Greater Boston/Cambridge	100%		_	170,821						
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs	100%		21,613	291,434						
421 Park Drive/Greater Boston/Fenway	100%			533,157						
401 Park Drive/Greater Boston/Fenway	100%		_	170,697				TE	BD	
40, 50, and 60 Sylvan Road/Greater Boston/Route 128	100%			480,940						
Other/Greater Boston	100%		_	157,989						
1450 Owens Street/San Francisco Bay Area/Mission Bay	25.0%		_	242,946						
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	50.0%		116,544	232,366		138,090		487,000	5.0%	5.1%
269 East Grand Avenue/San Francisco Bay Area/South San Francisco	100%		_	93,905				TE	<u>.</u>	
701 Dexter Avenue North/Seattle/Lake Union	100%			 283,261				16	טפ	
			138,157	2,657,516						
			1,083,784	3,786,381						
100% Pre-leased committed near-term project expected to commence constr	uction in the next year									
Campus Point by Alexandria/San Diego/University Town Center	55.0%		_	19,965		640,035		660,000	7.3%	6.5%
Total		\$	1,083,784	\$ 3,806,346	\$	2,880,000	(2)	7,780,000)	
Our share of investment ⁽²⁾⁽³⁾		\$	990,000	\$ 3,180,000	\$	2,440,000	\$	6,610,000		

Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2027 and beyond over the next several quarters.
- (2) Represents dollar amount rounded to the nearest \$10 million and includes preliminary estimated amounts for projects listed as TBD. Total cost to complete for our development and redevelopment projects under construction have not been adjusted for the potential impact related to higher materials costs associated with potential tariffs. We are still evaluating the potential impact on costs and returns that can be significantly impacted by tariffs, the amount of foreign materials required, and/or the higher cost of domestic materials.
- (3) Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects.



74% of Our Total Development and Redevelopment Pipeline RSF Is Within Our Megacampus[™] Ecosystems

Square Footage Development and Redevelopment Our Market Ownership Under Committed **Book Value** Construction **Near Term Future** Total⁽¹⁾ Property/Submarket Interest Greater Boston Megacampus: Alexandria Center® at One Kendall Square/Cambridge 100% 104.956 \$ 170.821 104.956 One Hampshire Street 370.202 Megacampus: The Arsenal on the Charles/Cambridge/Inner Suburbs 100% 348.966 34.157 404.359 311 Arsenal Street, 500 North Beacon Street, and 4 Kingsbury Avenue Megacampus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue/Cambridge/Inner Suburbs 308.792 204.395 902.000 1.106.395 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue Megacampus: Alexandria Center® for Life Science – Fenway/Fenway 100% 703.854 529.686 529.686 401 and 421 Park Drive Megacampus: Alexandria Center® for Life Science – Waltham/Route 128 100% 544.558 596.064 515.000 1.111.064 40, 50, and 60 Sylvan Road, and 35 Gatehouse Drive Megacampus: Alexandria Center® at Kendall Square/Cambridge 100% 209.528 174.500 174.500 100 Edwin H. Land Boulevard Megacampus: Alexandria Technology Square®/Cambridge 100% 8.239 100.000 100.000 Megacampus: 285, 299, 307, and 345 Dorchester Avenue/Seaport Innovation 60.0% District 293.055 1,040,000 1.040.000 10 Necco Street/Seaport Innovation District 100% 105.734 175.000 175.000 100% 112.000 112.000 215 Presidential Way/Route 128 6.816 100% 373,732 453,869 Other development and redevelopment projects 1,348,541 1,802,410 \$ 3,074,095 2,259,172 4,401,198 6,660,370

⁽¹⁾ Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.

⁽²⁾ We have a 76.9% interest in 99 Coolidge Avenue aggregating 204,395 RSF and a 100% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF.

June 30, 2025

(Dollars in thousands)



	Our		Developr	nent and Redevelop	ment	
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Future	Total ⁽¹⁾
San Francisco Bay Area						
Megacampus: Alexandria Center [®] for Science and Technology – Mission Bay/ Mission Bay	25.0%	\$ 242,946	212,796	_	_	212,796
1450 Owens Street						
Megacampus: Alexandria Technology Center® – Gateway/ South San Francisco	50.0%	258,932	237,684	_	291,000	528,684
651 Gateway Boulevard						
Megacampus: Alexandria Center [®] for Advanced Technologies – South San Francisco/South San Francisco	100%	100,560	107,250	_	90,000	197,250
211 ⁽³⁾ and 269 East Grand Avenue						
Megacampus: Alexandria Center [®] for Advanced Technologies – Tanforan/South San Francisco	100%	420,858	_	_	1,930,000	1,930,000
1122, 1150, and 1178 El Camino Real						
Alexandria Center® for Life Science – Millbrae/South San Francisco 201 and 231 Adrian Road and 30 Rollins Road	48.5%	157,008	_	_	348,401	348,401
Megacampus: Alexandria Center® for Life Science – San Carlos/Greater Stanford 960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road	100%	471,861	_	_	1,497,830	1,497,830
3825 and 3875 Fabian Way/Greater Stanford	100%	161,492	_	_	478,000	478,000
2100, 2200, 2300, and 2400 Geng Road/Greater Stanford	100%	38,761	_	_	240,000	240,000
Megacampus: 88 Bluxome Street/SoMa	100%	408,649		<u> </u>	1,070,925	1,070,925
		\$ 2,261,067	557,730		5,946,156	6,503,886

⁽¹⁾ Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment or properties. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.

⁽²⁾ During the three months ended December 31, 2024, we executed a letter of intent with a biomedical institution for the sale of a condominium interest aggregating 103,361 RSF, or approximately 49% of the development project. During the three months ended June 30, 2025, the institution decided to pursue a long-term lease instead of a condominium sale. As a result, we added back the 103,361 RSF and the related book basis to our presentation of the development project.

⁽³⁾ Includes a property in which we own a partial interest through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2025

(Dollars in thousands)



				Square Fo	ootage		
	Our		Develop	ment and Redevelop	ment		
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Future	Total ⁽¹⁾	
San Diego							
Megacampus: One Alexandria Square/Torrey Pines	100%	\$ 281,632	122,302	_	125,280	247,582	
10945 Alexandria Way and 10975 and 10995 Torreyana Road							
Megacampus: Campus Point by Alexandria/University Town Center	55.0% ⁽³⁾	540,207	426,927	466,598	500,859	1,394,384	
10010 ⁽²⁾ , 10140 ⁽²⁾ , 10210, and 10260 Campus Point Drive and 4135, 4161, 4165, and 4224 Campus Point Court							
Megacampus: SD Tech by Alexandria/Sorrento Mesa	50.0%	391,642	235,361	_	493,845	729,206	
9805 Scranton Road and 10075 Barnes Canyon Road							
11255 and 11355 North Torrey Pines Road/Torrey Pines	100%	156,121	_	_	215,000	215,000	
Megacampus: 5200 Illumina Way/University Town Center	51.0%	17,458	_	_	451,832	451,832	
9625 Towne Centre Drive/University Town Center	30.0%	837	_	_	100,000	100,000	
Megacampus: Sequence District by Alexandria/Sorrento Mesa	100%	47,565	_	_	1,661,915	1,661,915	
6290, 6310, 6340, 6350, and 6450 Sequence Drive							
Scripps Science Park by Alexandria/Sorrento Mesa	100%	42,700	_	_	154,308	154,308	
10256 and 10260 Meanley Drive							
4075 Sorrento Valley Boulevard/Sorrento Valley	100%	28,174	_	_	144,000	144,000	
Other development and redevelopment projects	(4)	78,002	_	_	475,000	475,000	
		\$ 1,584,338	784,590	466,598	4,322,039	5,573,227	

⁽¹⁾ Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.

⁽²⁾ We have a 100% interest in this property.

⁽³⁾ The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata with our partner.

⁽⁴⁾ Includes a property in which we own a partial interest through a real estate joint venture.

June 30, 2025

(Dollars in thousands)



			otage				
	Our		Develo	pment and Redevelop	ment		
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Future	Total ⁽¹⁾	
Seattle							
Megacampus: Alexandria Center® for Advanced Technologies – South Lake Union/ Lake Union	(2)	\$ 571,319	227,577	_	1,057,400	1,284,977	
601 and 701 Dexter Avenue North and 800 Mercer Street							
1010 4th Avenue South/SoDo	100%	61,490	_	_	544,825	544,825	
410 West Harrison Street/Elliott Bay	100%	_	_	_	91,000	91,000	
Megacampus: Alexandria Center® for Advanced Technologies – Canyon Park/ Bothell	100%	19,248	_	_	230,000	230,000	
21660 20th Avenue Southeast							
Other development and redevelopment projects	100%	149,289			706,087	706,087	
		801,346	227,577	_	2,629,312	2,856,889	
Maryland							
Megacampus: Alexandria Center® for Life Science – Shady Grove/Rockville 9830 Damestown Road	100%	24,020	_	_	296,000	296,000	
		24,020			296,000	296,000	
Research Triangle							
Megacampus: Alexandria Center® for Life Science – Durham/Research Triangle	100%	162,011	_	_	2,060,000	2,060,000	
Megacampus: Alexandria Center® for Advanced Technologies and AgTech – Research Triangle/Research Triangle	100%	109,661	_	_	1,170,000	1,170,000	
4 and 12 Davis Drive							
Megacampus: Alexandria Center [®] for NextGen Medicines/ Research Triangle	100%	112,142	_	_	1,055,000	1,055,000	
3029 East Cornwallis Road							
Megacampus: Alexandria Center® for Sustainable Technologies/Research Triangle	100%	55,122	_	_	750,000	750,000	
120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle Drive							
100 Capitola Drive/Research Triangle	100%	_	_	_	65,965	65,965	
Other development and redevelopment projects	100%	4,185			76,262	76,262	
		\$ 443,121			5,177,227	5,177,227	

⁽¹⁾ Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment or properties. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.

⁽²⁾ We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF.

June 30, 2025

(Dollars in thousands)



			ootage			
	Our		Develop			
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term Future		Total ⁽¹⁾
New York City						
Megacampus: Alexandria Center® for Life Science – New York City/New York City	100%	\$ 173,815	<u> </u>		550,000 (2)	550,000
		173,815	_	_	550,000	550,000
Texas						
Alexandria Center® for Advanced Technologies at The Woodlands/Greater Houston 8800 Technology Forest Place	100%	49,280	73,298	_	116,405	189,703
1001 Trinity Street and 1020 Red River Street/Austin	100%	10,858	_	_	250,010	250,010
Other development and redevelopment projects	100%	58,577			344,000	344,000
		118,715	73,298	_	710,415	783,713
Canada	100%	15,088	56,314	_	371,743	428,057
Other development and redevelopment projects	100%	47,478			350,000	350,000
Total pipeline as of June 30, 2025, excluding properties held for sale		8,543,083	3,958,681	466,598	24,754,090	29,179,369
Properties held for sale		82,269	_	_	878,205	878,205
Total pipeline as of June 30, 2025		\$ 8,625,352 (3)	3,958,681	466,598	25,632,295	30,057,574

- (1) Total square footage includes 2,578,478 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- (2) During the three months ended September 30, 2024, we filed a lawsuit against the New York City Health + Hospitals Corporation and the New York City Economic Development Corporation for fraud and breach of contract concerning our option to ground lease a land parcel to develop a future world-class life science building within the Alexandria Center® for Life Science New York City Megacampus. Refer to our quarterly report on Form 10-Q for the three months ended June 30, 2025 filed with the Securities and Exchange Commission on July 21, 2025 for additional details.
- (3) Includes \$3.8 billion of projects that are currently under construction and one 100% pre-leased committed near-term project expected to commence construction in the next year.

Construction Spending

June 30, 2025

(Dollars in thousands)



Construction spending		onths Ended e 30, 2025	Midpoir	ected Guidance nt for Year Ending ember 31, 2025	 ır Ended ber 31, 2024_
Construction of Class A/A+ properties:		_			
Active construction projects					
Under construction	\$	612,341	\$	1,240,000	\$ 1,791,097
Future pipeline pre-construction					
Primarily Megacampus expansion pre-construction work (entitlement, design, and site work)		226,587		500,000	426,948
Revenue- and non-revenue-enhancing capital expenditures		127,772		415,000 ⁽¹⁾	 273,377
Construction spending (before contributions from noncontrolling interests or tenants):		966,700		2,155,000	2,491,422
Contributions from noncontrolling interests (consolidated real estate joint ventures)		(113,268)		(230,000) (2)	(343,798)
Tenant-funded and -built landlord improvements		(171,153)		(175,000)	 (129,152)
Total construction spending	\$	682,279	\$	1,750,000	\$ 2,018,472
2025 guidance range for construction spending			\$1,450	,000 – \$2,050,000	

Projected capital contributions from partners in consolidated real estate joint ventures to fund construction

Timing	A	mount ⁽²⁾
3Q25 through 2026	\$	203,691
2027 and beyond		93,585
Total	\$	297,276


⁽¹⁾ Represents revenue-enhancing and non-revenue-enhancing capital expenditures before contributions from noncontrolling interests and tenant-funded and tenant-built landlord improvements for the year ending December 31, 2025. Our share of the 2025 revenue-enhancing and non-revenue-enhancing capital expenditures is projected to be \$340 million at the midpoint of our guidance for 2025 construction spending.

⁽²⁾ Represents contractual capital commitments from existing real estate joint venture partners to fund construction.



Alexandria Has Been Curating and Growing Highly Desirable and Well-Amenitized Megacampus Ecosystems In The Top Life Science Clusters For Nearly Two Decades

Key Categories of Real Estate Basis Capitalized	Leased/ Negotiating	Average Real Estate Basis Capitalized During 1H25	Average Real Estate Basis Capitalized
Construction of Class A/A+ properties:			
Development and redevelopment of projects under construction and one 100% pre-leased committed near-term project expected to commence construction in the next year			
2025 and 2026 stabilization	84%	\$ 767,453	10%
2027 and beyond stabilization	28%	2,102,723	26
Smaller redevelopments and repositioning capital projects		1,007,166 ⁽¹⁾	12
Key future Megacampus expansion pre-construction work		1,209,540 (2)	15
Future pipeline projects with key pre-construction milestones during 2H25 and 2026		2,979,991 (3)	37
Total average real estate basis capitalized		\$ 8,066,873	100%



Percentage of Total Average Real Estate Basis Capitalized During 1H25

- (1) Includes 668,795 RSF that is leased, but not yet delivered. The weighted-average expected delivery date is January 2, 2026.
- (2) Refer to the four projects on the following pages for additional details.
- (3) Includes future pipeline projects that are expected to reach anticipated pre-construction milestones, including various phases of entitlement, design, site work and other activities necessary to begin aboveground vertical construction, on April 3, 2026, on a weighted-average real estate investment basis. We will evaluate whether to proceed with future pre-construction and/or construction activities based on leasing demand and market conditions.



Key Future Megacampus[™] **Development Project**



Refer to "Megacampus™" under "Definitions and reconciliations" in the Supplemental Information for additional details.



Key Future Megacampus[™] **Development Project**



Refer to "Megacampus™" under "Definitions and reconciliations" in the Supplemental Information for additional details.



Key Active, Committed Near-Term, and Future Megacampus[™] Development Project



Refer to "Megacampus™" under "Definitions and reconciliations" in the Supplemental Information for additional details.



Key Active and Future Megacampus[™] Development Project



Refer to "Megacampus™" under "Definitions and reconciliations" in the Supplemental Information for additional details.



Consolidated Real Estate Joint Ventures

Property	Market	Submarket	Noncontrolling Interest Share	Operating RSF at 100%
50 and 60 Binney Street	Greater Boston	Cambridge/Inner Suburbs	66.0%	532,395
75/125 Binney Street	Greater Boston	Cambridge/Inner Suburbs	60.0%	388,270
100 and 225 Binney Street and 300 Third Street	Greater Boston	Cambridge/Inner Suburbs	70.0%	870,641
99 Coolidge Avenue ⁽¹⁾	Greater Boston	Cambridge/Inner Suburbs	23.1%	116,414
15 Necco Street	Greater Boston	Seaport Innovation District	43.3%	345,996
285, 299, 307, and 345 Dorchester Avenue	Greater Boston	Seaport Innovation District	40.0%	(1)
Alexandria Center® for Science and Technology – Mission Bay(2)	San Francisco Bay Area	Mission Bay	75.0%	1,013,997
601, 611, 651 ⁽¹⁾ , 681, 685, and 701 Gateway Boulevard	San Francisco Bay Area	South San Francisco	50.0%	874,234
751 Gateway Boulevard	San Francisco Bay Area	South San Francisco	49.0%	230,592
211 and 213 East Grand Avenue	San Francisco Bay Area	South San Francisco	70.0%	300,930
500 Forbes Boulevard	San Francisco Bay Area	South San Francisco	90.0%	155,685
Alexandria Center® for Life Science – Millbrae	San Francisco Bay Area	South San Francisco	51.5%	285,346
3215 Merryfield Row	San Diego	Torrey Pines	70.0%	170,523
Campus Point by Alexandria ⁽¹⁾⁽³⁾	San Diego	University Town Center	45.0% ⁽⁴⁾	1,212,414
5200 Illumina Way	San Diego	University Town Center	49.0%	792,687
9625 Towne Centre Drive	San Diego	University Town Center	70.0%	163,648
SD Tech by Alexandria ⁽¹⁾⁽⁵⁾	San Diego	Sorrento Mesa	50.0%	816,048
Pacific Technology Park	San Diego	Sorrento Mesa	50.0%	544,352
Summers Ridge Science Park ⁽⁶⁾	San Diego	Sorrento Mesa	70.0%	316,531
1201 and 1208 Eastlake Avenue East	Seattle	Lake Union	70.0%	206,134
199 East Blaine Street	Seattle	Lake Union	70.0%	115,084
400 Dexter Avenue North	Seattle	Lake Union	70.0%	290,754
800 Mercer Street	Seattle	Lake Union	40.0%	(1)

Unconsolidated Real Estate Joint Ventures

Property	Market	Submarket	Our Ownership Share ⁽⁷⁾	Operating RSF at 100%
1655 and 1725 Third Street	San Francisco Bay Area	Mission Bay	10.0%	586,208
1450 Research Boulevard	Maryland	Rockville	73.2% (8)	42,012
101 West Dickman Street	Maryland	Beltsville	58.4% ⁽⁸⁾	135,949

Refer to "Joint venture financial information" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents a property currently under construction or in our future development and redevelopment pipeline. Refer to the sections under "New Class A/A+ development and redevelopment properties" in the Supplemental Information for additional details.
- (2) Includes 409 and 499 Illinois Street, 1450, 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South.
- 3) Includes 10210, 10260, 10290, and 10300 Campus Point Drive and 4110, 4135, 4155, 4161, 4165, 4224, and 4242 Campus Point Court.
- (4) The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases from 55% to 75%, after which future capital would be contributed pro-rata with our partner. Refer to "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for additional details.
- (5) Includes 9605, 9645, 9675, 9725, 9735, 9805, 9808, 9855, and 9868 Scranton Road and 10055, 10065, and 10075 Barnes Canyon Road.
- (6) Includes 9965, 9975, 9985, and 9995 Summers Ridge Road.
- (7) In addition to the real estate joint ventures listed, we hold an interest in one insignificant unconsolidated real estate joint venture.
- (8) Represents a joint venture with a local real estate operator in which our joint venture partner manages the day-to-day activities that significantly affect the economic performance of the joint venture.



As of June 30, 2025

Investments in real estate
Cash, cash equivalents, and restricted cash
Other assets
Secured notes payable
Other liabilities
Redeemable noncontrolling interests

AS 01 Julie 30, 2023					
Noncontrolling Interest Share of Consolidated Real Estate JVs		Unc	ur Share of onsolidated I Estate JVs		
\$	4,250,023	\$	99,775		
	144,770		2,917		
	457,402		10,156		
	(35,448)		(67,378)		
	(252,979)		(5,236)		
	(9,612)		_		
\$	4,554,156	\$	40,234		

Noncontrolling Interest Share of Consolidated Real Estate JVs

Our Share of Unconsolidated Real Estate JVs

	June 30, 2025					June 30), 2025		
		Months Ended	Six Months Ended		Three Months Ended		Six M	onths Ended	
Total revenues	\$	117,958	\$	234,595	\$	2,688	\$	5,263	
Rental operations		(36,039)		(70,808)		(935)		(1,983)	
		81,919		163,787		1,753		3,280	
General and administrative		(930)		(1,563)		(62)		(81)	
Interest		(330)		(754)		(1,097)		(2,058)	
Depreciation and amortization of real estate assets		(36,047)		(69,458)		(942)		(1,996)	
Impairment of real estate		_		_		(8,673)		(8,673)	
Fixed returns allocated to redeemable noncontrolling interests ⁽¹⁾		201		402		_		_	
	\$	44,813	\$	92,414	\$	(9,021)	\$	(9,528)	
Straight-line rent and below-market lease revenue	\$	6,542	\$	10,194	\$	176	\$	334	
Funds from operations ⁽¹⁾	\$	80,860	\$	161,872	\$	594	\$	1,141	

Refer to "Joint venture financial information" under "Definitions and reconciliations" in the Supplemental Information for additional details.

⁽¹⁾ Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release and "Definitions and reconciliations" in the Supplemental Information for additional details.

Investments

June 30, 2025

(Dollars in thousands)




We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. The tables below summarize components of our investment income (loss) and non-real estate investments. Refer to "Investments" under "Definitions and reconciliations" in the Supplemental Information for additional details.


		June 3	Year Ended					
	Three	Months Ended	Six I	Months Ended	December 31, 2024			
Realized (losses) gains	\$	(8,684) ⁽¹⁾	\$	9,469 ⁽¹⁾	\$	59,124 ⁽²⁾		
Unrealized losses		(21,938) ⁽³⁾		(90,083) ⁽⁴⁾	\$	(112,246) ⁽⁵⁾		
Investment loss	\$	(30,622)	\$	(80,614)	\$	(53,122)		

	June 30, 2025									cember 31, 2024
Investments	Cost			Unrealized Gains		Unrealized Losses		Carrying Amount		arrying Amount
Publicly traded companies	\$	183,859	9	\$ 18,365	\$	(120,299)	\$	81,925	\$	105,667
Entities that report NAV		497,975		97,201		(43,013)		552,163		609,866
Entities that do not report NAV:										
Entities with observable price changes		78,105		64,585		(9,156)		133,534		174,737
Entities without observable price changes		432,299		_		_		432,299		400,487
Investments accounted for under the equity method		N/A		N/A		N/A		276,775		186,228
June 30, 2025	\$	1,192,238	(6)	\$ 180,151	\$	(172,468)	\$	1,476,696	\$	1,476,985
December 31, 2024	\$	1,207,146	9	\$ 228,100	\$	(144,489)	\$	1,476,985		

Public/Private Mix (Cost)

Tenant/Non-Tenant Mix (Cost)





- (1) Consists of realized gains of \$30.5 million and \$59.9 million, partially offset by impairment charges of \$39.2 million and \$50.4 million during the three and six months ended June 30, 2025, respectively.
- (2) Consists of realized gains of \$117.2 million, partially offset by impairment charges aggregating \$58.1 million during the year ended December 31, 2024.
- (3) Consists of unrealized gains of \$12.5 million primarily resulting from the increase in fair values of our investments in publicly traded entities and investments in privately held entities that report NAV and \$34.4 million resulting from accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the three months ended June 30, 2025.
- (4) Primarily relates to the accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the six months ended June 30, 2025.
- (5) Primarily relates to the accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the year ended December 31, 2024.
- (6) Represents 2.7% of gross assets as of June 30, 2025. Refer to "Gross assets" under "Definitions and reconciliations" in the Supplemental Information for additional details.



ALEXANDRIA CONTINUES TO HAVE A STRONG AND FLEXIBLE BALANCE SHEET WITH SIGNIFICANT LIQUIDITY

TOP 10%

CREDIT RATING RANKING AMONG ALL PUBLICLY TRADED U.S. REITS⁽¹⁾ BBB+

Stable

Baa1 Stable

MOODY'S RATINGS

S&P Global

Ratings



9%

One of the Lowest Debt Maturities for 2025-2027 Among S&P 500 REITs⁽³⁾

PERCENTAGE OF FIXED-RATE DEBT SINCE 2021⁽²⁾

97.2%

REMAINING DEBT TERM (IN YEARS)

12.0

DEBT INTEREST RATE

4.01%

WEIGHTED AVERAGE

As of June 30, 2025. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Top 10% ranking represents credit rating levels from S&P Global Ratings and Moody's Ratings for publicly traded U.S. REITs, from Bloomberg Professional Services and Nareit, as of June 30, 2025.
- Represents the quarterly average percentage fixed-rate debt as of each quarter end from January 1, 2021 through June 30, 2025.
- 3) Sources: J.P. Morgan, "REIT Detailed Debt Maturities as of March 31, 2025" or company filings as of March 31, 2025, except ARE, which is as of June 30, 2025.




Liquidity


\$4.6B

(in millions)	
Availability under our unsecured senior line of credit, net of amounts outstanding under our commercial paper program	\$ 3,900
Cash, cash equivalents, and restricted cash	528
Availability under our secured construction loan	42
Investments in publicly traded companies	82
Liquidity as of June 30, 2025	\$ 4,552

Minimal Outstanding Borrowings and Significant Availability on Unsecured Senior Line of Credit




Net Debt and Preferred Stock to Adjusted EBITDA⁽¹⁾




Refer to "Definitions and reconciliations" in the Supplemental Information for additional details. Quarter annualized.

Fixed-Charge Coverage Ratio⁽¹⁾





Weighted-Average Remaining Term of 12.0 Years



⁽¹⁾ We expect to have limited borrowings outstanding on our unsecured senior line of credit and commercial paper program by the end of 2025. We expect to reduce the outstanding balance with proceeds from our 2025 dispositions.

⁽²⁾ Refer to footnotes 2 through 4 on page 57 under "Fixed-rate and variable-rate debt" for additional details.



ALEXANDRIA HAS THE LONGEST WEIGHTED-AVERAGE REMAINING DEBT TERM AMONG S&P 500 REITS AT 2X THE AVERAGE DEBT TERM FOR THESE REITS



Sources: S&P Global Market Intelligence, Bloomberg, or company filings (data not disclosed for PSA) as of March 31, 2025, except for ARE, which is as of June 30, 2025.

Summary of Debt (continued)

June 30, 2025

(Dollars in thousands)



Fixed-rate and variable-rate debt Weighted-Average **Fixed-Rate** Variable-Rate **Remaining Term** Interest Rate⁽¹⁾ Debt Debt **Total Percentage** (in years) \$ \$ 153,500 \$ 153,500 1.2% 7.16% Secured note payable 1.4 Unsecured senior notes payable 12,042,607 12,042,607 90.5 3.90 12.8 Unsecured senior line of credit(2) and commercial paper program⁽³⁾ 1,097,993 8.3 4.6 1,097,993 4.71 12,042,607 1,251,493 13,294,100 100.0% 4.01% 12.0 Total/weighted average Percentage of total debt 90.6% 9.4% 100.0%

(2) As of June 30, 2025, we had no outstanding balance on our unsecured senior line of credit.

⁽⁴⁾ We calculate the weighted-average remaining term of our commercial paper notes by using the maturity date of our unsecured senior line of credit. Using the maturity date of our outstanding commercial paper notes, the consolidated weighted-average maturity of our debt is 11.6 years. The commercial paper notes sold during the six months ended June 30, 2025 were issued at a weighted-average yield to maturity of 4.67% and had a weighted-average maturity term of 16 days.

	Average Debt Outstanding				Weighted-Average Interest Rate			
		June 30, 2025			June 30, 2025			
	Thi	Three Months Ended Six Months Ended 1		Three Months Ended	Six Months Ended			
Long-term fixed-rate debt	\$	\$ 12,314,715		12,374,695	3.88%	3.85%		
Short-term variable-rate unsecured senior line of credit and commercial paper program debt		926,720		651,302	4.70	4.65		
Blended-average interest rate		13,241,435		13,025,997	3.94	3.89		
Loan fee amortization and annual facility fee related to unsecured senior line of credit		N/A		N/A	0.13	0.14		
Total/weighted average	\$	13,241,435	\$	13,025,997	4.07%	4.03%		
Short-term variable-rate unsecured senior line of credit and commercial paper program debt Blended-average interest rate Loan fee amortization and annual facility fee related to unsecured senior line of credit	\$	926,720 13,241,435 N/A	\$	651,302 13,025,997 N/A	4.70 3.94 0.13	4.65 3.89 0.14		

⁽¹⁾ Represents the weighted-average interest rate as of the end of the applicable period, including expense/income related to the amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.

⁽³⁾ The commercial paper program provides us with the ability to issue up to \$2.5 billion of commercial paper notes that bear interest at short-term fixed rates and can generally be issued with a maturity of 30 days or less and with a maximum maturity of 397 days from the date of issuance. Borrowings under the program are used to fund short-term capital needs and are backed by our unsecured senior line of credit. In the event we are unable to issue commercial paper notes or refinance outstanding borrowings under terms equal to or more favorable than those under our unsecured senior line of credit, we expect to borrow under the unsecured senior line of credit at SOFR+0.855%. As of June 30, 2025, we had \$1.1 billion of commercial paper notes outstanding.

Summary of Debt (continued)

June 30, 2025

(Dollars in thousands)



Debt covenants	Unsecured Seni	or Notes Payable	Unsecured Senior Line of Credit			
Debt Covenant Ratios ⁽¹⁾	Requirement	June 30, 2025	Requirement	June 30, 2025		
Total Debt to Total Assets	≤ 60%	31%	≤ 60.0%	32.2%		
Secured Debt to Total Assets	≤ 40%	0.4%	≤ 45.0%	0.3%		
Consolidated EBITDA to Interest Expense	≥ 1.5x	10.6x	≥ 1.50x	3.71x		
Unencumbered Total Asset Value to Unsecured Debt	≥ 150%	309%	N/A	N/A		
Unsecured Interest Coverage Ratio	N/A	N/A	≥ 1.75x	9.30x		

⁽¹⁾ All covenant ratio titles utilize terms as defined in the respective debt and credit agreements. The calculation of consolidated EBITDA is based on the definitions contained in our loan agreements and is not directly comparable to the computation of EBITDA as described in Exchange Act Release No. 47226.

Unconsolidated real estate joint ventures' debt

Unconsolidated Joint Venture	Maturity Date	Stated Rate	Interest Rate ⁽¹⁾	ggregate mmitment	Debt	Balance ⁽²⁾	Our Share
101 West Dickman Street	11/10/26	SOFR+1.95% (3)	6.34%	\$ 26,750	\$	19,081	58.4%
1450 Research Boulevard	12/10/26	SOFR+1.95% (3)	6.40%	13,000		8,965	73.2%
1655 and 1725 Third Street	2/10/35	6.37%	6.44%	500,000		496,709	10.0%
				\$ 539,750	\$	524,755	

⁽¹⁾ Includes interest expense and amortization of loan fees.

At 100%

⁽²⁾ Represents outstanding principal, net of unamortized deferred financing costs, as of June 30, 2025.

⁽³⁾ This loan is subject to a fixed SOFR floor of 0.75%.

Summary of Debt (continued)

June 30, 2025

(Dollars in thousands)



Unamortized

											(Deferred Financing	
	Stated	Interest	Maturity	Princi	oal Payments	Remaining	for the Perio	ds Ending D	ecember 31,		Cost), (Discount)/	
Debt	Rate	Interest Rate ⁽¹⁾	Date ⁽²⁾	2025	2026	2027	2028	2029	Thereafter	Principal	Premium	Total
Secured note payable												
Greater Boston ⁽³⁾	SOFR+2.70%	7.16%	11/19/26 (3)	\$ —	\$ 153,624	\$ —	\$ —	\$ —	\$ —	\$ 153,624	\$ (124) \$ 153,500
Unsecured senior line of credit and commercial paper program ⁽⁴⁾	(4)	4.71 (4)	1/22/30 (4)	_	_	_	_	_	1,100,000	1,100,000	(2,007) 1,097,993
Unsecured senior notes payable	4.30%	4.50	1/15/26	_	300,000	_	_	_	_	300,000	(284) 299,716
Unsecured senior notes payable	3.80%	3.96	4/15/26	_	350,000	_	_	_	_	350,000	(408) 349,592
Unsecured senior notes payable	3.95%	4.13	1/15/27	_	_	350,000	_	_	_	350,000	(812) 349,188
Unsecured senior notes payable	3.95%	4.07	1/15/28	_	_	_	425,000	_	_	425,000	(1,100) 423,900
Unsecured senior notes payable	4.50%	4.60	7/30/29	_	_	_	_	300,000	_	300,000	(916) 299,084
Unsecured senior notes payable	2.75%	2.87	12/15/29	_	_	_	_	400,000	_	400,000	(1,860) 398,140
Unsecured senior notes payable	4.70%	4.81	7/1/30	_	_	_	_	_	450,000	450,000	(1,872) 448,128
Unsecured senior notes payable	4.90%	5.05	12/15/30	_	_	_	_	_	700,000	700,000	(4,339) 695,661
Unsecured senior notes payable	3.375%	3.48	8/15/31	_	_	_	_	_	750,000	750,000	(4,027) 745,973
Unsecured senior notes payable	2.00%	2.12	5/18/32	_	_	_	_	_	900,000	900,000	(6,506	, ,
Unsecured senior notes payable	1.875%	1.97	2/1/33	_	_	_	_	_	1,000,000	1,000,000	(6,675) 993,325
Unsecured senior notes payable	2.95%	3.07	3/15/34	_	_	_	_	_	800,000	800,000	(6,857	,
Unsecured senior notes payable	4.75%	4.88	4/15/35	_	_	_	_	_	500,000	500,000	(4,730	,
Unsecured senior notes payable	5.50%	5.66	10/1/35	_	_	_	_	_	550,000	550,000	(6,624) 543,376
Unsecured senior notes payable	5.25%	5.38	5/15/36	_	_	_	_	_	400,000	400,000	(3,939) 396,061
Unsecured senior notes payable	4.85%	4.93	4/15/49	_	_	_	_	_	300,000	300,000	(2,814) 297,186
Unsecured senior notes payable	4.00%	3.91	2/1/50	_	_	_	_	_	700,000	700,000	9,916	709,916
Unsecured senior notes payable	3.00%	3.08	5/18/51	_	_	_	_	_	850,000	850,000	(11,034) 838,966
Unsecured senior notes payable	3.55%	3.63	3/15/52	_	_	_	_	_	1,000,000	1,000,000	(13,450) 986,550
Unsecured senior notes payable	5.15%	5.26	4/15/53	_	_	_	_	_	500,000	500,000	(7,482) 492,518
Unsecured senior notes payable	5.625%	5.71	5/15/54						600,000	600,000	(6,580	593,420
Unsecured debt weighted-average interest rate/ subtotal		3.97			650,000	350,000	425,000	700,000	11,100,000	13,225,000	(84,400) 13,140,600
Weighted-average interest rate/total		4.01%		\$ —	\$ 803,624	\$ 350,000	\$ 425,000	\$ 700,000	\$11,100,000	\$13,378,624	\$ (84,524) \$13,294,100
Balloon payments				\$ —	\$ 803,624	\$ 350,000	\$ 425,000	\$ 700,000	\$11,100,000	\$13,378,624	\$ —	\$13,378,624
Principal amortization				_	_	_	_	_	_	_	(84,524) (84,524)
Total debt				\$ —	\$ 803,624	\$ 350,000	\$ 425,000	\$ 700,000	\$11,100,000	\$13,378,624	\$ (84,524	\$13,294,100
Fixed-rate debt				\$ —	\$ 650,000	\$ 350,000	\$ 425,000	\$ 700,000	\$ 10,000,000	\$12,125,000	\$ (82,393	\$12,042,607
Variable-rate debt				_	153,624	_	_	_	1,100,000	1,253,624	(2,131	
Total debt				\$ _	\$ 803,624	\$ 350,000	\$ 425,000	\$ 700,000	\$ 11,100,000	\$13,378,624	\$ (84,524	\$13,294,100
Weighted-average stated rate on maturing debt				N/A	3.78%	3.95%	3.95%	3.50%	3.88%			

⁽¹⁾ Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.

⁽²⁾ Reflects any extension options that we control.

⁽³⁾ Represents a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, where we have a 76.9% interest. As of June 30, 2025, this joint venture has \$41.7 million available under existing lender commitments. We expect to repay the entire \$153.5 million balance in August 2025.

⁽⁴⁾ Refer to footnotes 2 through 4 under "Fixed-rate and variable-rate debt" in "Summary of debt" for additional details.

Definitions and Reconciliations

June 30, 2025



This section contains additional details for sections throughout the Supplemental Information and the accompanying Earnings Press Release, as well as explanations and reconciliations of certain non-GAAP financial measures and the reasons why we use these supplemental measures of performance and believe they provide useful information to investors. Additional detail can be found in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as other documents filed with or furnished to the SEC from time to time.

Adjusted EBITDA and Adjusted EBITDA margin

The following table reconciles net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted EBITDA and calculates the Adjusted EBITDA margin:

	Three Months Ended								
(Dollars in thousands)		6/30/25		3/31/25		12/31/24		9/30/24	6/30/24
Net (loss) income	\$	(62,189)	\$	38,662	\$	(16,095)	\$	213,603	\$ 94,049
Interest expense		55,296		50,876		55,659		43,550	45,789
Income taxes		1,020		1,145		1,855		1,877	1,182
Depreciation and amortization		346,123		342,062		330,108		293,998	290,720
Stock compensation expense		12,530		10,064		12,477		15,525	14,507
Gain on sales of real estate		_		(13,165)		(101,806)		(27,114)	_
Unrealized losses (gains) on non-real estate investments		21,938		68,145		79,776		(2,610)	64,238
Impairment of real estate		129,606		32,154		186,564		5,741	30,763
Impairment of non-real estate investments		39,216		11,180		20,266		10,338	12,788
Increase (decrease) in provision for expected credit losses on financial instruments				285		(434)			
Adjusted EBITDA	\$	543,540	\$	541,408	\$	568,370	\$	554,908	\$ 554,036
Total revenues	\$	762,040	\$	758,158	\$	788,945	\$	791,607	\$ 766,734
Adjusted EBITDA margin		71%		71%		72%		70%	72%

We use Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization ("EBITDA"), excluding stock compensation expense, gains or losses on early extinguishment of debt, gains or losses on sales of real estate, impairments of real estate, changes in provision for expected credit losses on financial instruments, and significant termination fees. Adjusted EBITDA also excludes unrealized gains or losses and significant realized gains or losses and impairments that result from our non-real estate investments. These non-real estate investment amounts are classified in our consolidated statements of operations outside of total revenues.

We believe Adjusted EBITDA provides investors with relevant and useful information as it allows investors to evaluate the operating performance of our business activities without having to account for differences recognized because of investing and financing decisions related to our real estate and non-real estate investments, our capital structure, capital market transactions, and variances resulting from the volatility of market conditions outside of our control. For example, we exclude gains or losses on the early extinguishment of debt to allow investors to measure our performance independent of our indebtedness and capital structure. We believe that adjusting for the effects of impairments and gains or losses on sales of real estate, significant impairments and realized gains or losses on non-real estate investments, changes in provision for expected credit losses on financial instruments, and significant termination fees allows investors to evaluate performance from period to period on a consistent basis without having to account for differences recognized because of investing and financing decisions related to our real estate and non-real estate investments or other corporate activities that may not be representative of the operating performance of our properties.

In addition, we believe that excluding charges related to stock compensation and unrealized gains or losses facilitates for investors a comparison of our business activities across periods without the volatility resulting from market forces outside of our control. Adjusted EBITDA has limitations as a measure of our performance. Adjusted EBITDA does not reflect our historical expenditures or future requirements for capital expenditures or contractual commitments. While Adjusted EBITDA is a relevant measure of performance, it does not represent net income (loss) or cash flows from operations calculated and presented in accordance with GAAP, and it should not be considered as an alternative to those indicators in evaluating performance or liquidity.

In order to calculate the Adjusted EBITDA margin, we divide Adjusted EBITDA by total revenues as presented in our consolidated statements of operations. We believe that this supplemental performance measure provides investors with additional useful information regarding the profitability of our operating activities.

We are not able to forecast the net income of future periods without unreasonable effort and therefore do not provide a reconciliation for Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairments of non-real estate investments, and changes in provision for expected credit losses on financial instruments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

June 30, 2025



Annual rental revenue

Annual rental revenue represents the annualized fixed base rental obligations, calculated in accordance with GAAP, including the amortization of deferred revenue related to tenant-funded and tenant-built landlord improvements, for leases in effect as of the end of the period, related to our operating RSF. Annual rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue for our unconsolidated real estate joint ventures. Annual rental revenue per RSF is computed by dividing annual rental revenue by the sum of 100% of the RSF of our consolidated properties and our share of the RSF of properties held in unconsolidated real estate joint ventures. As of June 30, 2025, approximately 91% of our leases (on annual rental revenue basis) were triple net leases, which require tenants to pay substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other operating expenses (including increases thereto) in addition to base rent. Annual rental revenue excludes these operating expenses recovered from our tenants. Amounts recovered from our tenants related to these operating expenses, along with base rent, are classified in income from rentals in our consolidated statements of operations.

Capitalization rates

Capitalization rates are calculated based on net operating income and net operating income (cash basis) annualized, excluding lease termination fees, on stabilized operating assets for the quarter preceding the date on which the property is sold, or near-term prospective net operating income.

Capitalized interest

We capitalize interest cost as a cost of a project during periods for which activities necessary to develop, redevelop, or reposition a project for its intended use are ongoing, provided that expenditures for the asset have been made and interest cost has been incurred. Activities necessary to develop, redevelop, or reposition a project include pre-construction activities such as entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. If we cease activities necessary to prepare a project for its intended use, interest costs related to such project are expensed as incurred.

Cash interest

Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of loan fees and debt premiums (discounts). Refer to the definition of fixed-charge coverage ratio for a reconciliation of interest expense, the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest.

Class A/A+ properties and AAA locations

Class A/A+ properties are properties clustered in AAA locations that provide innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. These properties are typically well-located, professionally managed, and well-maintained, offering a wide range of amenities and featuring premium construction materials and finishes. Class A/A+ properties are generally newer or have undergone substantial redevelopment and are generally expected to command higher annual rental rates compared to other classes of similar properties. AAA locations are in close proximity to concentrations of specialized skills, knowledge, institutions, and related businesses. It is important to note that our definition of property classification may not be directly comparable to other equity REITs.

Credit ratings

Represents the credit ratings assigned by S&P Global Ratings or Moody's Ratings as of June 30, 2025. A credit rating is not a recommendation to buy, sell, or hold securities and may be subject to revision or withdrawal at any time.

Development, redevelopment, and pre-construction

A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new Class A/A+ properties, as well as property enhancements identified during the underwriting of certain acquired properties. These efforts are primarily concentrated in collaborative Megacampus™ ecosystems within AAA life science innovation clusters, as well as other strategic locations that support innovation and growth. These projects are generally focused on providing high-quality, generic, and reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each development or redevelopment project is expected to generate increases in rental income, net operating income, and cash flows. Our development and redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Development projects generally consist of the ground-up development of generic and reusable laboratory facilities. Redevelopment projects consist of the permanent change in use of acquired office, warehouse, or shell space into laboratory space. We generally will not commence new development projects for aboveground construction of new Class A/A+ laboratory space without first securing significant pre-leasing for such space, except when there is solid market demand for high-quality Class A/A+ properties.

Pre-construction activities include entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. Ultimately, these projects will provide high-quality facilities and are expected to generate significant revenue and cash flows.

Development, redevelopment, and pre-construction spending also includes the following costs: (i) amounts to bring certain acquired properties up to market standard and/or other costs identified during the acquisition process (generally within two years of acquisition) and (ii) permanent conversion of space for highly flexible, move-in-ready laboratory space to foster the growth of promising early- and growth-stage life science companies.

June 30, 2025



Development, redevelopment, and pre-construction (continued)

Revenue-enhancing and repositioning capital expenditures represent spending to reposition or significantly change the use of a property, including through improvement in the asset quality from Class B to Class A/A+.

Non-revenue-enhancing capital expenditures represent costs required to maintain the current revenues of a stabilized property, including the associated costs for renewed and re-leased space.

Dividend payout ratio (common stock)

Dividend payout ratio (common stock) is the ratio of the absolute dollar amount of dividends on our common stock (shares of common stock outstanding on the respective record dates multiplied by the related dividend per share) to funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted.

Dividend yield

Dividend yield for the quarter represents the annualized quarter dividend divided by the closing common stock price at the end of the quarter.

Space Intentionally Blank

Fixed-charge coverage ratio

Fixed-charge coverage ratio is a non-GAAP financial measure representing the ratio of Adjusted EBITDA to cash interest and fixed charges. We believe that this ratio is useful to investors as a supplemental measure of our ability to satisfy fixed financing obligations and preferred stock dividends. Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of loan fees and debt premiums (discounts).

The following table reconciles interest expense, the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest and computes fixed-charge coverage ratio:

	Three Months Ended									
(Dollars in thousands)		6/30/25		3/31/25	1	12/31/24		9/30/24		6/30/24
Adjusted EBITDA	\$	543,540	\$	541,408	\$	568,370	\$	554,908	\$	554,036
Interest expense	\$	55,296	\$	50,876	\$	55,659	\$	43,550	\$	45,789
Capitalized interest		82,423		80,065		81,586		86,496		81,039
Amortization of loan fees		(4,615)		(4,691)		(4,620)		(4,222)		(4,146)
Amortization of debt discounts		(335)		(349)		(333)		(330)		(328)
Cash interest and fixed charges	\$	132,769	\$	125,901	\$	132,292	\$	125,494	\$	122,354
Fixed-charge coverage ratio:										
 quarter annualized 		4.1x		4.3x		4.3x		4.4x		4.5x
 trailing 12 months 		4.3x		4.4x		4.5x		4.5x		4.6x

We are not able to forecast the net income of future periods without unreasonable effort and therefore do not provide a reconciliation for fixed-charge coverage ratio on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, impairments of non-real estate investments, and changes in provision for expected credit losses on financial instruments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

June 30, 2025



Funds from operations and funds from operations, as adjusted, attributable to Alexandria's common stockholders

GAAP-basis accounting for real estate assets utilizes historical cost accounting and assumes that real estate values diminish over time. In an effort to overcome the difference between real estate values and historical cost accounting for real estate assets, the Nareit Board of Governors established funds from operations as an improved measurement tool. Since its introduction, funds from operations has become a widely used non-GAAP financial measure among equity REITs. We believe that funds from operations is helpful to investors as an additional measure of the performance of an equity REIT. Moreover, we believe that funds from operations, as adjusted, allows investors to compare our performance to the performance of other real estate companies on a consistent basis, without having to account for differences recognized because of real estate acquisition and disposition decisions, financing decisions, capital structure, capital market transactions, variances resulting from the volatility of market conditions outside of our control, or other corporate activities that may not be representative of the operating performance of our properties.

The 2018 White Paper published by the Nareit Board of Governors (the "Nareit White Paper") defines funds from operations as net income (computed in accordance with GAAP), excluding gains or losses on sales of real estate, and impairments of real estate, plus depreciation and amortization of operating real estate assets, and after adjustments for our share of consolidated and unconsolidated partnerships and real estate joint ventures. Impairments represent the write-down of assets when fair value over the recoverability period is less than the carrying value due to changes in general market conditions and do not necessarily reflect the operating performance of the properties during the corresponding period.

We compute funds from operations, as adjusted, as funds from operations calculated in accordance with the Nareit White Paper, excluding significant gains, losses, and impairments realized on non-real estate investments, unrealized gains or losses on non-real estate investments, impairments of real estate primarily consisting of right-of-use assets and pre-acquisition costs related to projects that we decided to no longer pursue, gains or losses on early extinguishment of debt, changes in the provision for expected credit losses on financial instruments, significant termination fees, acceleration of stock compensation expense due to the resignations of executive officers, deal costs, the income tax effect related to such items, and the amount of such items that is allocable to our unvested restricted stock awards. We compute the amount that is allocable to our unvested restricted stock awards with nonforfeitable dividends using the two-class method. Under the two-class method, we allocate net income (after amounts attributable to noncontrolling interests) to common stockholders and to unvested restricted stock awards with nonforfeitable dividends by applying the respective weighted-average shares outstanding during each quarter-to-date and year-to-date period. This may result in a difference of the summation of the quarter-to-date and year-to-date amounts. Neither funds from operations nor funds from operations, as adjusted, should be considered as alternatives to net income (determined in accordance with GAAP) as indications of financial performance, or to cash flows from operating activities (determined in accordance with GAAP) as measures of liquidity, nor are they indicative of the availability of funds for our cash needs, including our ability to make distributions.

Funds from operations and funds from operations, as adjusted, attributable to Alexandria's common stockholders (continued)

The following table reconciles net income (loss) to funds from operations for the share of consolidated real estate joint ventures attributable to noncontrolling interests and our share of unconsolidated real estate joint ventures:

	controlling l ensolidated F			Our Share of Unconsolidated Real Estate JVs					
	June 3	0, 202	5	June 30, 2025					
(In thousands)	 ee Months Ended		x Months Ended		e Months Ended	Six Months Ended			
Net income (loss)	\$ 44,813	\$ 92,414		\$	(9,021)	\$	(9,528)		
Depreciation and amortization of real estate assets	36,047		69,458		942		1,996		
Impairment of real estate	 				8,673		8,673		
Funds from operations	\$ 80,860	\$	161,872	\$	594	\$	1,141		

Gross assets

Gross assets are calculated as total assets plus accumulated depreciation:

(In thousands)	6/30/25	3/31/25		3/31/25		3/31/25		12/31/24		12/31/24 9/30/2		6/30/24
Total assets	\$ 37,623,629	\$	37,600,428	\$	37,527,449	\$	38,488,128	\$ 37,847,865				
Accumulated depreciation	6,146,378		5,886,561		5,625,179		5,624,642	5,457,414				
Gross assets	\$ 43,770,007	\$	43,486,989	\$	43,152,628	\$	44,112,770	\$ 43,305,279				

Incremental annual net operating income on development and redevelopment projects

Incremental annual net operating income represents the amount of net operating income, on an annual basis, expected to be realized upon a project being placed into service and achieving full occupancy. Incremental annual net operating income is calculated as the initial stabilized yield multiplied by the project's total cost at completion.

Initial stabilized yield (unlevered)

Initial stabilized yield is calculated as the estimated amounts of net operating income at stabilization divided by our investment in the property. For this calculation, we exclude any tenant-funded and tenant-built landlord improvements from our investment in the property. Our initial stabilized yield excludes the benefit of leverage. Our cash rents related to our development and redevelopment projects are generally expected to increase over time due to contractual annual rent escalations. Our estimates for initial stabilized yields, initial stabilized yields (cash basis), and total costs at completion represent our initial estimates at the commencement of the project. We expect to update this information upon completion of the project, or sooner if there are significant changes to the expected project yields or costs.

- Initial stabilized yield reflects rental income, including contractual rent escalations and any rent
 concessions over the term(s) of the lease(s), calculated on a straight-line basis, and any
 amortization of deferred revenue related to tenant-funded and tenant-built landlord improvements.
- Initial stabilized yield (cash basis) reflects cash rents at the stabilization date after initial rental concessions, if any, have elapsed and our total cash investment in the property.

June 30, 2025



Investment-grade or publicly traded large cap tenants

Investment-grade or publicly traded large cap tenants represent tenants that are investment-grade rated or publicly traded companies with an average daily market capitalization greater than \$10 billion for the twelve months ended June 30, 2025, as reported by Bloomberg Professional Services. Credit ratings from Moody's Ratings and S&P Global Ratings reflect credit ratings of the tenant's parent entity, and there can be no assurance that a tenant's parent entity will satisfy the tenant's lease obligation upon such tenant's default. We monitor the credit quality and related material changes of our tenants. Material changes that cause a tenant's market capitalization to decrease below \$10 billion, which are not immediately reflected in the twelve-month average, may result in their exclusion from this measure.

Investments

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. We recognize, measure, present, and disclose these investments as follows:

		Statements of Operations						
	Balance Sheet	Gain	s and Losses					
	Carrying Amount	Unrealized	Realized					
Publicly traded companies	Fair value	Changes in fair value						
Privately held entities without readily determinable fair values that:			Difference between proceeds received upon disposition and historical cost					
Report NAV	Fair value, using NAV as a practical expedient	Changes in NAV, as a practical expedient to fair value						
Do not report NAV	Cost, adjusted for observable price changes and impairments ⁽¹⁾	Observable price changes ⁽¹⁾	Impairments to reduce costs to fair value, which result in an adjusted cost basis and the differences between proceeds received upon disposition and adjusted or historical cost					
Equity method investments	Contributions, adjusted for our share of the investee's earnings or losses, less distributions received, reduced by other-than-temporary impairments	Our share of unrealized gains or losses reported by the investee	Our share of realized gains or losses reported by the investee, and other-than- temporary impairments					

⁽¹⁾ An observable price is a price observed in an orderly transaction for an identical or similar investment of the same issuer. Observable price changes result from, among other things, equity transactions for the same issuer with similar rights and obligations executed during the reporting period, including subsequent equity offerings or other reported equity transactions related to the same issuer.

Investments in real estate

The following table reconciles our investments in real estate as of June 30, 2025:

(In thousands)	 vestments in Real Estate
Gross investments in real estate	\$ 38,306,978
Less: accumulated depreciation	 (6,146,378)
Investments in real estate	\$ 32,160,600

The following table presents our new Class A/A+ development and redevelopment pipeline, excluding properties held for sale, as a percentage of gross assets and as a percentage of annual rental revenue as of June 30, 2025:

		Perc	entage of
(Dollars in thousands)	 ook Value	Gross Assets	Annual Rental Revenue
Under construction and committed near-term projects	\$ 3,806,346	9%	-%
Income-producing/potential cash flows/covered land play(1)	3,183,092	7	1
Land	1,553,645	4	
	\$ 8,543,083	20%	1%

Includes projects with existing buildings that are generating or can generate operating cash flows. Also includes
development rights associated with existing operating campuses.

Space Intentionally Blank

June 30, 2025



Investments in real estate (continued)

The square footage presented in the table below is classified as operating as of June 30, 2025. These lease expirations or vacant space at recently acquired properties represent future opportunities for which we have the intent, subject to market conditions and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development:

	Dev/	RSF of Lease Expirations Targeted for Development and Redevelopment							
Property/Submarket	Redev	2025	2026	Thereafter ⁽¹⁾	Total				
Committed near-term project:									
Campus Point by Alexandria/University Town Center	Dev	_	_	52,620	52,620				
Future projects:									
446, 458, 500, and 550 Arsenal Street/Cambridge/ Inner Suburbs	Dev	_	_	365,898	365,898				
Other/Greater Boston	Redev	_	_	167,549	167,549				
1122 and 1150 El Camino Real/South San Francisco	Dev	_	_	375,232	375,232				
3875 Fabian Way/Greater Stanford	Dev	_	_	228,000	228,000				
2100 and 2200 Geng Road/Greater Stanford	Dev	_	_	62,526	62,526				
960 Industrial Road/Greater Stanford	Dev	_	_	112,590	112,590				
Campus Point by Alexandria/University Town Center	Dev	_	_	96,805	96,805				
Sequence District by Alexandria/Sorrento Mesa	Dev/ Redev	_	_	555,754	555,754				
410 West Harrison Street/Elliott Bay	Dev	_	_	17,205	17,205				
Other/Seattle	Dev	_	_	63,057	63,057				
100 Capitola Drive/Research Triangle	Dev	_	_	34,527	34,527				
1001 Trinity Street and 1020 Red River Street/Austin	Dev/ Redev	198,972	_	_	198,972				
Canada	Redev			247,743	247,743				
		198,972		2,326,886	2,525,858				
Total		198,972		2,379,506	2,578,478				

⁽¹⁾ Includes vacant square footage as of June 30, 2025.

Joint venture financial information

We present components of balance sheet and operating results information related to our real estate joint ventures, which are not presented, or intended to be presented, in accordance with GAAP. We present the proportionate share of certain financial line items as follows: (i) for each real estate joint venture that we consolidate in our financial statements, which are controlled by us through contractual rights or majority voting rights, but of which we own less than 100%, we apply the noncontrolling interest economic ownership percentage to each financial item to arrive at the amount of such cumulative noncontrolling interest share of each component presented; and (ii) for each real estate joint venture that we do not control and do not consolidate, which are instead controlled jointly or by our joint venture partners through contractual rights or majority voting rights, we apply our economic ownership percentage to each financial item to arrive at our proportionate share of each component presented.

The components of balance sheet and operating results information related to our real estate joint ventures do not represent our legal claim to those items. For each entity that we do not wholly own, the joint venture agreement generally determines what equity holders can receive upon capital events, such as sales or refinancing, or in the event of a liquidation. Equity holders are normally entitled to their respective legal ownership of any residual cash from a joint venture only after all liabilities, priority distributions, and claims have been repaid or satisfied.

We believe that this information can help investors estimate the balance sheet and operating results information related to our partially owned entities. Presenting this information provides a perspective not immediately available from consolidated financial statements and one that can supplement an understanding of the joint venture assets, liabilities, revenues, and expenses included in our consolidated results.

The components of balance sheet and operating results information related to our real estate joint ventures are limited as an analytical tool as the overall economic ownership interest does not represent our legal claim to each of our joint ventures' assets, liabilities, or results of operations. In addition, joint venture financial information may include financial information related to the unconsolidated real estate joint ventures that we do not control. We believe that in order to facilitate for investors a clear understanding of our operating results and our total assets and liabilities, joint venture financial information should be examined in conjunction with our consolidated statements of operations and balance sheets. Joint venture financial information should not be considered an alternative to our consolidated financial statements, which are presented and prepared in accordance with GAAP.

Space Intentionally Blank

June 30, 2025



Key items included in net income attributable to Alexandria's common stockholders

We present a tabular comparison of items, whether gain or loss, that may facilitate a highlevel understanding of our results and provide context for the disclosures included in this Supplemental Information, our most recent annual report on Form 10-K, and our subsequent quarterly reports on Form 10-Q. We believe that such tabular presentation promotes a better understanding for investors of the corporate-level decisions made and activities performed that significantly affect comparison of our operating results from period to period. We also believe that this tabular presentation will supplement for investors an understanding of our disclosures and real estate operating results. Gains or losses on sales of real estate and impairments of assets classified as held for sale are related to corporate-level decisions to dispose of real estate. Gains or losses on early extinguishment of debt are related to corporate-level financing decisions focused on our capital structure strategy. Significant realized and unrealized gains or losses on non-real estate investments, impairments of real estate and non-real estate investments, and acceleration of stock compensation expense due to the resignation of an executive officer are not related to the operating performance of our real estate assets as they result from strategic, corporate-level non-real estate investment decisions and external market conditions. Impairments of non-real estate investments and changes in the provision for expected credit losses on financial instruments are not related to the operating performance of our real estate as they represent the write-down of non-real estate investments when their fair values decrease below their respective carrying values due to changes in general market or other conditions outside of our control. Significant items, whether a gain or loss, included in the tabular disclosure for current periods are described in further detail in this Supplemental Information and accompanying Earnings Press Release.

Megacampus™

A Megacampus ecosystem is a cluster campus that consist of approximately 1 million RSF or greater, including operating, active development/redevelopment, and land RSF less operating RSF expected to be demolished. The following table reconciles our annual rental revenue and development and redevelopment pipeline RSF as of June 30, 2025:

(Dollars in thousands)	A	nnual Rental Revenue	Redevelopment Pipeline RSF
Megacampus	\$	1,570,877	20,370,529
Core and non-core		510,353	7,108,567
Total	\$	2,081,230	27,479,096
Megacampus as a percentage of annual rental revenue and of total development and redevelopment pipeline RSF		75%	74%

Net cash provided by operating activities after dividends

Net cash provided by operating activities after dividends is reduced by distributions to noncontrolling interests and excludes changes in operating assets and liabilities as they represent timing differences.

Net debt and preferred stock to Adjusted EBITDA

Net debt and preferred stock to Adjusted EBITDA is a non-GAAP financial measure that we believe is useful to investors as a supplemental measure of evaluating our balance sheet leverage. Net debt and preferred stock is equal to the sum of total consolidated debt less cash, cash equivalents, and restricted cash, plus preferred stock outstanding as of the end of the period. Refer to the definition of Adjusted EBITDA and Adjusted EBITDA margin for further information on the calculation of Adjusted FBITDA.

The following table reconciles debt to net debt and preferred stock and computes the ratio to Adjusted EBITDA:

(Dollars in thousands)	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24
Secured notes payable	\$ 153,500	\$ 150,807	\$ 149,909	\$ 145,000	\$ 134,942
Unsecured senior notes payable	12,042,607	12,640,144	12,094,465	12,092,012	12,089,561
Unsecured senior line of credit and commercial paper	1,097,993	299,883	_	454,589	199,552
Unamortized deferred financing costs	78,574	80,776	77,649	79,610	81,942
Cash and cash equivalents	(520,545)	(476,430)	(552,146)	(562,606)	(561,021)
Restricted cash	(7,403)	(7,324)	(7,701)	(17,031)	(4,832)
Preferred stock					
Net debt and preferred stock	\$12,844,726	\$12,687,856	\$11,762,176	\$12,191,574	\$11,940,144
Adjusted EBITDA:					
 quarter annualized 	\$2,174,160	\$2,165,632	\$2,273,480	\$2,219,632	\$2,216,144
trailing 12 months	\$2,208,226	\$2,218,722	\$2,228,921	\$2,184,298	\$2,122,250
Net debt and preferred stock to Adjusted	EBITDA:				
 quarter annualized 	5.9x	5.9x	5.2x	5.5x	5.4x
- trailing 12 months	5.8x	5.7x	5.3x	5.6x	5.6x

We are not able to forecast the net income of future periods without unreasonable effort and therefore do not provide a reconciliation for net debt and preferred stock to Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, impairment of non-real estate investments, and provision for expected credit losses on financial instruments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

June 30, 2025



Net operating income, net operating income (cash basis), and operating margin

The following table reconciles net income (loss) to net operating income and net operating income (cash basis) and computes operating margin:

		Three Months Ended			Six Months Ended			
(Dollars in thousands)		6/30/25		6/30/24		6/30/25		6/30/24
Net (loss) income	\$	(62,189)	\$	94,049	\$	(23,527)	\$	313,225
Equity in losses (earnings) of unconsolidated real estate joint ventures		9,021		(130)		9,528		(285)
General and administrative expenses		29,128		44,629		59,803		91,684
Interest expense		55,296		45,789		106,172		86,629
Depreciation and amortization		346,123		290,720		688,185		578,274
Impairment of real estate		129,606		30,763		161,760		30,763
Gain on sales of real estate		_		_		(13,165)		(392)
Investment loss		30,622		43,660		80,614		376
Net operating income		537,607		549,480		1,069,370		1,100,274
Straight-line rent revenue		(18,536)		(48,338)		(40,559)		(96,589)
Amortization of deferred revenue related to tenant- funded and -built landlord improvements		(2,401)		_		(4,052)		_
Amortization of acquired below-market leases		(10,196)		(22,515)		(25,418)		(52,855)
Provision for expected credit losses on financial instruments						285		
Net operating income (cash basis)	\$	506,474	\$	478,627	\$	999,626	\$	950,830
Net operating income (cash basis) – annualized	\$	2,025,896	\$	1,914,508	\$	1,999,252	\$	1,901,660
Net operating income (from above)	\$	537,607	\$	549,480	\$	1,069,370	\$	1,100,274
Total revenues	\$	762,040	\$	766,734	\$	1,520,198	\$	1,535,842
Operating margin	_	71%	_	72%	_	70%	_	72%

Net operating income is a non-GAAP financial measure calculated as net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP. excluding equity in the earnings of our unconsolidated real estate joint ventures, general and administrative expenses, interest expense, depreciation and amortization, impairments of real estate, gains or losses on early extinguishment of debt, gains or losses on sales of real estate, and investment income or loss. We believe net operating income provides useful information to investors regarding our financial condition and results of operations because it primarily reflects those income and expense items that are incurred at the property level. Therefore, we believe net operating income is a useful measure for investors to evaluate the operating performance of our consolidated real estate assets. Net operating income on a cash basis is net operating income adjusted to exclude the effect of straight-line rent, amortization of acquired above- and below-market lease revenue, amortization of deferred revenue related to tenant-funded and tenant-built landlord improvements, and changes in the provision for expected credit losses on financial instruments required by GAAP. We believe that net operating income on a cash basis is helpful to investors as an additional measure of operating performance because it eliminates straight-line rent revenue and the amortization of acquired above- and below-market leases and tenant-funded and tenant-built landlord improvements.

Net operating income, net operating income (cash basis), and operating margin (continued)

Furthermore, we believe net operating income is useful to investors as a performance measure of our consolidated properties because, when compared across periods, net operating income reflects trends in occupancy rates, rental rates, and operating costs, which provide a perspective not immediately apparent from net income or loss. Net operating income can be used to measure the initial stabilized yields of our properties by calculating net operating income generated by a property divided by our investment in the property. Net operating income excludes certain components from net income in order to provide results that are more closely related to the results of operations of our properties. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level rather than at the property level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort comparability of operating performance at the property level. Impairments of real estate have been excluded in deriving net operating income because we do not consider impairments of real estate to be property-level operating expenses. Impairments of real estate relate to changes in the values of our assets and do not reflect the current operating performance with respect to related revenues or expenses. Our impairments of real estate represent the write-down in the value of the assets to the estimated fair value less cost to sell. These impairments result from investing decisions or a deterioration in market conditions. We also exclude realized and unrealized investment gain or loss, which results from investment decisions that occur at the corporate level related to non-real estate investments in publicly traded companies and certain privately held entities. Therefore, we do not consider these activities to be an indication of operating performance of our real estate assets at the property level. Our calculation of net operating income also excludes charges incurred from changes in certain financing decisions, such as losses on early extinguishment of debt and changes in provision for expected credit losses on financial instruments, as these charges often relate to corporate strategy. Property operating expenses included in determining net operating income primarily consist of costs that are related to our operating properties, such as utilities, repairs, and maintenance; rental expense related to ground leases; contracted services, such as janitorial, engineering, and landscaping; property taxes and insurance; and property-level salaries. General and administrative expenses consist primarily of accounting and corporate compensation, corporate insurance, professional fees, rent, and supplies that are incurred as part of corporate office management. We calculate operating margin as net operating income divided by total revenues.

We believe that in order to facilitate for investors a clear understanding of our operating results, net operating income should be examined in conjunction with net income or loss as presented in our consolidated statements of operations. Net operating income should not be considered as an alternative to net income or loss as an indication of our performance, nor as an alternative to cash flows as a measure of our liquidity or our ability to make distributions.

Operating statistics

We present certain operating statistics related to our properties, including number of properties, RSF, occupancy percentage, leasing activity, and contractual lease expirations as of the end of the period. We believe these measures are useful to investors because they facilitate an understanding of certain trends for our properties. We compute the number of properties, RSF, occupancy percentage, leasing activity, and contractual lease expirations at 100%, excluding RSF at properties classified as held for sale, for all properties in which we have an investment, including properties owned by our consolidated and unconsolidated real estate joint ventures. For operating metrics based on annual rental revenue, refer to the definition of annual rental revenue herein.

June 30, 2025



Same property comparisons

As a result of changes within our total property portfolio during the comparative periods presented, including changes from assets acquired or sold, properties placed into development or redevelopment, and development or redevelopment properties recently placed into service, the consolidated total income from rentals, as well as rental operating expenses in our operating results, can show significant changes from period to period. In order to supplement an evaluation of our results of operations over a given quarterly or annual period, we analyze the operating performance for all consolidated properties that were fully operating for the entirety of the comparative periods presented, referred to as same properties. We separately present quarterly and year-to-date same property results to align with the interim financial information required by the SEC in our management's discussion and analysis of our financial condition and results of operations. These same properties are analyzed separately from properties acquired subsequent to the first day in the earliest comparable quarterly or year-to-date period presented, properties that underwent development or redevelopment at any time during the comparative periods, unconsolidated real estate joint ventures, properties classified as held for sale, and corporate entities (legal entities performing general and administrative functions), which are excluded from same property results. Additionally, termination fees, if any, are excluded from the results of same properties.

Space Intentionally Blank

Same property comparisons (continued)

The following table reconciles the number of same properties to total properties for the six months ended June 30, 2025:

Development – under construction	Properties
99 Coolidge Avenue	1
500 North Beacon Street and 4 Kingsbury Avenue	2
1450 Owens Street	1
10935, 10945, and 10955 Alexandria Way	3
10075 Barnes Canyon Road	1
421 Park Drive	1
4135 Campus Point Court	1
701 Dexter Avenue North	1
	11
Development – placed into	
service after January 1, 2024	Properties
9810 Darnestown Road	1
9820 Darnestown Road	1
1150 Eastlake Avenue East	1
4155 Campus Point Court	1
201 Brookline Avenue	1
9808 Medical Center Drive	1
230 Harriet Tubman Way	1
	7
Redevelopment – under construction	Properties
40, 50, and 60 Sylvan Road	3
269 East Grand Avenue	1
651 Gateway Boulevard	1
401 Park Drive	1
8800 Technology Forest Place	1
311 Arsenal Street	1
One Hampshire Street	1
Canada	4
Other	2
	15

Redevelopment – placed into service after January 1, 2024	Properties
840 Winter Street	1
Alexandria Center [®] for Advanced Technologies – Monte Villa Parkway	6
	7
Acquisitions after January 1, 2024	Properties
Other	3
	3
Unconsolidated real estate JVs	4
Properties held for sale	8
Total properties excluded from same properties	55
Same properties	329
Total properties in North America as of June 30, 2025	384

June 30, 2025



Stabilized occupancy date

The stabilized occupancy date represents the estimated date on which the project is expected to reach occupancy of 95% or greater.

Tenant recoveries

Tenant recoveries represent revenues comprising reimbursement of real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other operating expenses and earned in the period during which the applicable expenses are incurred and the tenant's obligation to reimburse us arises

We classify rental revenues and tenant recoveries generated through the leasing of real estate assets within revenues in income from rentals in our consolidated statements of operations. We provide investors with a separate presentation of rental revenues and tenant recoveries in "Same property performance" in this Supplemental Information because we believe it promotes investors' understanding of our operating results. We believe that the presentation of tenant recoveries is useful to investors as a supplemental measure of our ability to recover operating expenses under our triple net leases, including recoveries of utilities, repairs and maintenance, insurance, property taxes, common area expenses, and other operating expenses, and of our ability to mitigate the effect to net income for any significant variability to components of our operating expenses.

The following table reconciles income from rentals to tenant recoveries:

		Thre	Six Months Ended				
(In thousands)	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24	6/30/25	6/30/24
Income from rentals	\$ 737,279	\$ 743,175	\$ 763,249	\$ 775,744	\$ 755,162	\$1,480,454	\$1,510,713
Rental revenues	(553,377)	(552,112)	(566,535)	(579,569)	(576,835)	(1,105,489)	(1,158,235)
Tenant recoveries	\$ 183,902	\$ 191,063	\$ 196,714	\$ 196,175	\$ 178,327	\$ 374,965	\$ 352,478

Total equity capitalization

Total equity capitalization is equal to the outstanding shares of common stock multiplied by the closing price on the last trading day at the end of each period presented.

Total market capitalization

Total market capitalization is equal to the sum of total equity capitalization and total debt.

Unencumbered net operating income as a percentage of total net operating income

Unencumbered net operating income as a percentage of total net operating income is a non-GAAP financial measure that we believe is useful to investors as a performance measure of the results of operations of our unencumbered real estate assets as it reflects those income and expense items that are incurred at the unencumbered property level. Unencumbered net operating income is derived from assets classified in continuing operations, which are not subject to any mortgage, deed of trust, lien, or other security interest, as of the period for which income is presented.

The following table summarizes unencumbered net operating income as a percentage of total net operating income:

	I hree Months Ended							
(Dollars in thousands)	6/30/25		3/31/25	_	12/31/24		9/30/24	6/30/24
Unencumbered net operating income	\$ 535,766	\$	530,691	\$	547,921	\$	553,589	\$ 544,268
Encumbered net operating income	1,841		1,072		592		4,753	 5,212
Total net operating income	\$ 537,607	\$	531,763	\$	548,513	\$	558,342	\$ 549,480
Unencumbered net operating income as a percentage of total net operating income	99.7%		99.8%		99.9%		99.1%	 99.1%

Weighted-average interest rate for capitalization of interest

The weighted-average interest rate required for calculating capitalization of interest pursuant to GAAP represents a weighted-average rate as of the end of the applicable period, based on the rates applicable to borrowings outstanding during the period, including expense/income related to interest rate hedge agreements, amortization of loan fees, amortization of debt premiums (discounts), and other bank fees. A separate calculation is performed to determine our weighted-average interest rate for capitalization for each month. The rate will vary each month due to changes in variable interest rates, outstanding debt balances, the proportion of variable-rate debt to fixed-rate debt, the amount and terms of interest rate hedge agreements, and the amount of loan fee and premium (discount) amortization.

Space Intentionally Blank

June 30, 2025



Weighted-average shares of common stock outstanding - diluted

From time to time, we enter into capital market transactions, including forward equity sales agreements ("Forward Agreements"), to fund acquisitions, to fund construction of our development and redevelopment projects, and for general working capital purposes. While the Forward Agreements are outstanding, we are required to consider the potential dilutive effect of our Forward Agreements under the treasury stock method. Under this method, we also include the dilutive effect of unvested restricted stock awards ("RSAs") with forfeitable dividends in the calculation of diluted shares.

The weighted-average shares of common stock outstanding used in calculating EPS – diluted, FFO per share – diluted, and FFO per share – diluted, as adjusted, during each period are calculated as follows. Also shown are the weighted-average unvested shares associated with unvested RSAs with nonforfeitable dividends used in calculating amounts allocable to these awards pursuant to the two-class method for each of the respective periods presented below.

		Thre	e Months Er	nded		Six Months Ended		
(In thousands)	6/30/25	3/31/25	12/31/24	9/30/24	6/30/24	6/30/25	6/30/24	
Basic shares for earnings per share	170,135	170,522	172,262	172,058	172,013	170,328	171,981	
Unvested RSAs with forfeitable dividends								
Diluted shares for earnings per share	170,135	170,522	172,262	172,058	172,013	170,328	171,981	
Basic shares for funds from operations per share and funds from operations per share, as adjusted	170,135	170,522	172,262	172,058	172,013	170,328	171,981	
Unvested RSAs with forfeitable dividends	57	77	_	_	_	62	_	
Diluted shares for funds from operations per share and funds from operations per share, as adjusted	170,192	170,599	172,262	172,058	172,013	170,390	171,981	
Weighted-average unvested RSAs with nonforfeitable dividends used in calculating the allocations of net income, funds from operations, and funds from operations, as adjusted	1,998	2,053	2,417	2,838	2,878	2,025	2,933	